<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html xmlns="http://www.w3.org/1999/xhtml"><head>


<title>
	AccessMedicine | Carcinoma of the Female Breast
</title><link rel="stylesheet" href="Chapter%2017.%20Breast%20Disorders_archivos/Global.css" type="text/css"><link rel="stylesheet" href="Chapter%2017.%20Breast%20Disorders_archivos/layout.css" type="text/css">
	<script language="javascript" src="Chapter%2017.%20Breast%20Disorders_archivos/Global.js" type="text/javascript"></script>
    <script language="javascript" src="Chapter%2017.%20Breast%20Disorders_archivos/jquery-1.js" type="text/javascript"></script>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><link href="Chapter%2017.%20Breast%20Disorders_archivos/WebResource.css" type="text/css" rel="stylesheet" class="Telerik_stylesheet"><link href="Chapter%2017.%20Breast%20Disorders_archivos/WebResource_003.css" type="text/css" rel="stylesheet" class="Telerik_stylesheet"><link href="Chapter%2017.%20Breast%20Disorders_archivos/WebResource_004.css" type="text/css" rel="stylesheet" class="Telerik_stylesheet"><link href="Chapter%2017.%20Breast%20Disorders_archivos/WebResource_002.css" type="text/css" rel="stylesheet" class="Telerik_stylesheet"></head><body style="margin: 0px; background-color: white;" id="pageBody">
    <form name="aspnetForm" method="post" action="content.aspx?aID=8612&amp;searchStr=mammography" id="aspnetForm">
<div>
<input name="__EVENTTARGET" id="__EVENTTARGET" value="" type="hidden">
<input name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" type="hidden">
<input name="__VIEWSTATE" id="__VIEWSTATE" value="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" type="hidden">
</div>

<script type="text/javascript">
//<![CDATA[
var theForm = document.forms['aspnetForm'];
if (!theForm) {
    theForm = document.aspnetForm;
}
function __doPostBack(eventTarget, eventArgument) {
    if (!theForm.onsubmit || (theForm.onsubmit() != false)) {
        theForm.__EVENTTARGET.value = eventTarget;
        theForm.__EVENTARGUMENT.value = eventArgument;
        theForm.submit();
    }
}
//]]>
</script>


<script src="Chapter%2017.%20Breast%20Disorders_archivos/WebResource.axd" type="text/javascript"></script>


<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_006.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_004.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_003.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_011.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_008.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_010.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_007.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_002.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_005.axd" type="text/javascript"></script>
<script src="Chapter%2017.%20Breast%20Disorders_archivos/ScriptResource_009.axd" type="text/javascript"></script>
<div>

	<input name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEWAwL/iNzNBALc94ayBAKZ+MLCAcRZ2YacTkw0lQ37oB+uWrhz1Pra" type="hidden">
</div>
    <div id="maincontainermaster">
    <script type="text/javascript">
//<![CDATA[
Sys.WebForms.PageRequestManager._initialize('ctl00$ScriptManager1', document.getElementById('aspnetForm'));
Sys.WebForms.PageRequestManager.getInstance()._updateControls([], [], [], 90);
//]]>
</script>

    <div id="topsectionmaster">

<script type="text/javascript" language="javascript">
	function MM_preloadImages() {
		var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
		var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
		if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
	}
	MM_preloadImages('/images/header08/mast_go_over.jpg','/images/header08/tab_home_over.jpg','/images/header08/tab_clinical_over.jpg','/images/header08/tab_lange_over.jpg','/images/header08/tab_updates_over.jpg','/images/header08/tab_index_over.jpg','/images/header08/tab_images_over.jpg','/images/header08/tab_my_over.jpg','/images/header08/tab_customcurric_over.jpg');

    function PrepareForAutoComp(sender, eventArgs)
    {
        if (eventArgs.get_text().length < 3)
            eventArgs.set_cancel(true);
        else {
           var context = eventArgs.get_context();
        }
    }
    
    function OnClientSelectedIndexChanged(sender, eventArgs)
            {
                headerDoSearch();   
            }
    
    function GetLocation()
    {
        var strLocation = "/search/searchAM.aspx";
        var combo = $find("ctl00_ucheader1_RadcboSource");
        var searchSource = combo.get_value();
        
        if(searchSource=="1")
        {
            strLocation = "/search/searchAMImg.aspx";
        }
        return strLocation;
    }
      
   function OnClientDropDownOpening(sender, eventArgs)
   {
       if(sender.get_items().get_count() == 0)
         eventArgs.set_cancel(true);
   }

    
    function headerDoSearch() {
        var combo = $find("ctl00_ucheader1_RadComboBox2"); 
        var searchStr = combo.get_text();
        var combo2 = $find("ctl00_ucheader1_RadcboSource"); 
        var sourceStr = combo2.get_value();
        
        if (searchStr.length==0) {
            alert("Please input a search string.");
        } else {
            document.body.focus();
            document.location.href= GetLocation() + "?searchStr=" + encodeURI(searchStr) + "&sourceStr=" + sourceStr;
        }
    }

    function headerCheckSearchEnter(sender, eventArgs) {
        if (eventArgs.get_domEvent().keyCode == 13)  
        {  
            headerDoSearch(); 
        }  
    } 
    
    function SearchComboClick()
        {  
             headerDoSearch();   
    }

     function GetAgeID()
      {
        var vInput = "&ageID=0";
        if(document.getElementsByName("ageID").item(1).checked)
        {
            var vInput = "&ageID=2";
         }
         return vInput;
      }
  
     function URLEncode (clearString) {
        var output = '';
        var x = 0;
        clearString = clearString.toString();
        var regex = /(^[a-zA-Z0-9_.]*)/;
        while (x < clearString.length) {
            var match = regex.exec(clearString.substr(x));
            if (match != null && match.length > 1 && match[1] != '') {
                output += match[1];
                x += match[1].length;
            } else {
                if (clearString[x] == ' ') {
                    output += '+';
                } else {
                    var charCode = clearString.charCodeAt(x);
                    var hexVal = charCode.toString(16);
                    output += '%' + ( hexVal.length < 2 ? '0' : '' ) + hexVal.toLowerCase();
                }
                x++;
            }
        }
        return output;
    }
    
    function setCookie(c_name,value,expiredays)
    {
        var exdate=new Date();
        exdate.setDate(exdate.getDate()+expiredays);
        document.cookie=c_name+ "=" +escape(value)+
        ((expiredays==null) ? "" : ";expires="+exdate.toGMTString());
    }

    function showAboutSearch(url) {
        var oWindow = radopen (url,'aboutSearch');
        oWindow.Center
        oWindow.SetSize (700,500);
    }
    function checkCookie() {
    }
</script>

<table id="ctl00_ucheader1_tableMain" border="0" cellpadding="0" cellspacing="0" width="100%">
	<tbody><tr>
		<td>
            <table bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">
                <tbody><tr height="77">
                    <td width="30">
                    </td>
                    <td valign="top">
                        <table border="0" cellpadding="0" cellspacing="0" height="100%" width="100%">
                            <tbody><tr>
                                <td>
                                    <a href="http://www.accessmedicine.com/home.aspx">
                                        <img src="Chapter%2017.%20Breast%20Disorders_archivos/mast_logo.gif" alt="McGraw Hill's AccessMedicine" border="0"></a></td>
                                <td align="right" valign="top">
                                    <table border="0" cellpadding="0" cellspacing="0" height="100%" width="100%">
                                        <tbody><tr>
                                            <td align="right" valign="top">
                                                <table border="0" cellpadding="2" cellspacing="0">
                                                    <tbody><tr>
                                                        <td class="font10noMargin" align="right" valign="top">
                                                            <a href="http://www.accessmedicine.com/AtoZindex.aspx" class="solidNoUnderline">A-Z&nbsp;Index</a>&nbsp;&nbsp;&nbsp;<a href="http://books.mcgraw-hill.com/medical/libraryresources/accessMedicine/" target="new" class="solidNoUnderline">Librarians</a>&nbsp;&nbsp;&nbsp;<a href="http://www.accessmedicine.com/public/newsLetterSignUp.aspx" class="solidNoUnderline">Newsletter</a>&nbsp;&nbsp;&nbsp;<a href="https://store.accessmedicine.com/" class="solidNoUnderline">Subscriptions</a>&nbsp;&nbsp;&nbsp;<a href="http://www.accessmedicine.com/public/about_am.aspx" class="solidNoUnderline">About</a>&nbsp;&nbsp;&nbsp;<a target="_blank" href="http://books.mcgraw-hill.com/medical/accessmedicine/demo/" class="solidNoUnderline">Site Demo</a>&nbsp;&nbsp;&nbsp;<a href="http://www.accessmedicine.com/public/advisoryBoard.aspx" class="solidNoUnderline">Advisory&nbsp;Board</a> &nbsp;&nbsp;<a href="http://www.accessmedicine.com/public/contactus.aspx" class="solidNoUnderline">Contact&nbsp;Us</a>&nbsp;&nbsp;&nbsp;<a href="http://www.accessmedicine.com/public/helpHome.aspx" class="solidNoUnderline">Help</a>
                                                        </td>
                                                    </tr>
                                                </tbody></table>
                                                &nbsp;&nbsp;&nbsp;
                                            </td>
                                            <td align="right" valign="top">
                                                <table border="0" cellpadding="5" cellspacing="0">
                                                    <tbody><tr>
                                                        <td class="font10noMargin" align="right" valign="top">
                                                            <a href="http://www.mhprofessional.com/templates/116-medical.php" target="_blank">
                                                                <img src="Chapter%2017.%20Breast%20Disorders_archivos/mast_squarelogo.gif" alt="McGraw-Hill Medical" border="0"></a></td>
                                                    </tr>
                                                </tbody></table>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td colspan="2" align="right">
                                                <table border="0" cellpadding="4" cellspacing="0">
                                                    <tbody><tr>
                                                        <td class="font10noMargin">
                                                            <span id="ctl00_ucheader1_lblAccountInfo"><b>Universidad del Valle</b></span>
                                                            <b></b>
                                                            
                                                            <a href="http://www.accessmedicine.com/logout.aspx" id="ctl00_ucheader1_lnkLogOut">  Log Out</a></td>
                                                    </tr>
                                                </tbody></table>
                                            </td>
                                        </tr>
                                    </tbody></table>
                                </td>
                            </tr>
                        </tbody></table>
                    </td>
                    <td width="30">
                    </td>
                </tr>
                <tr style="background-image: url(/images/header08/tile_globalnav.jpg); background-repeat: repeat-x;">
                    <td style="width: 30px;">
                    </td>
                    <td valign="top">
                        <table border="0" cellpadding="0" cellspacing="0">
                            <tbody><tr valign="top">
                                <td valign="top">
                                    <a href="http://www.accessmedicine.com/home.aspx">
                                        <img name="home" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_home.jpg" onmouseover="home.src='/images/header08/tab_home_over.jpg'" onmouseout="home.src='/images/header08/tab_home.jpg'" alt="Home" border="0"></a></td>
                                <td id="ctl00_ucheader1_tdTextbooks" valign="top">
                                    <a href="http://www.accessmedicine.com/textbooks.aspx">
                                        <img name="imgtextbooks" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_textbooks.jpg" onmouseover="imgtextbooks.src='/images/header08/tab_textbooks_over.jpg'" onmouseout="imgtextbooks.src='/images/header08/tab_textbooks.jpg'" alt="Textbooks" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdVideoAudio" valign="top">
                                    <a href="http://www.accessmedicine.com/audioVideo.aspx">
                                        <img name="videoaudio" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_videoaudio.jpg" onmouseover="videoaudio.src='/images/header08/tab_videoaudio_over.jpg'" onmouseout="videoaudio.src='/images/header08/tab_videoaudio.jpg'" alt="Video &amp; Audio" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdSelfAssesment" valign="top">
                                    <a href="http://www.accessmedicine.com/selfAssessments.aspx">
                                        <img name="selfassessment" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_selfassess.jpg" onmouseover="selfassessment.src='/images/header08/tab_selfassess_over.jpg'" onmouseout="selfassessment.src='/images/header08/tab_selfassess.jpg'" alt="Self Assessments" border="0"></a></td>
		
                                <td valign="top">
                                    <a href="http://www.accessmedicine.com/drugs.aspx">
                                        <img name="drugs" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_drugs.jpg" onmouseover="drugs.src='/images/header08/tab_drugs_over.jpg'" onmouseout="drugs.src='/images/header08/tab_drugs.jpg'" alt="Drugs" border="0"></a></td>
                                <td id="ctl00_ucheader1_tdUpdates" valign="top">
                                    <a href="http://www.accessmedicine.com/updates.aspx">
                                        <img name="updates" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_updates.jpg" onmouseover="updates.src='/images/header08/tab_updates_over.jpg'" onmouseout="updates.src='/images/header08/tab_updates.jpg'" alt="Updates" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tddxTests" valign="top">
                                    <a href="http://www.accessmedicine.com/pocketDiagnostic.aspx">
                                        <img name="dxTests" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_dxtests.jpg" onmouseover="dxTests.src='/images/header08/tab_dxtests_over.jpg'" onmouseout="dxTests.src='/images/header08/tab_dxtests.jpg'" alt="dxTests" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tddiagnosaurus" valign="top">
                                    <a href="http://www.accessmedicine.com/diag.aspx">
                                        <img name="diagnosaurus" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_ddx.jpg" onmouseover="diagnosaurus.src='/images/header08/tab_ddx_over.jpg'" onmouseout="diagnosaurus.src='/images/header08/tab_ddx.jpg'" alt="Diagnosaurus" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdguidelines" valign="top">
                                    <a href="http://www.accessmedicine.com/guidelines.aspx">
                                        <img name="guidelines" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_guidelines.jpg" onmouseover="guidelines.src='/images/header08/tab_guidelines_over.jpg'" onmouseout="guidelines.src='/images/header08/tab_guidelines.jpg'" alt="Guidelines" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdquickam" valign="top">
                                    <a href="http://www.accessmedicine.com/quickam.aspx">
                                        <img name="quickam" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_quickanswers.jpg" onmouseover="quickam.src='/images/header08/tab_quickanswers_over.jpg'" onmouseout="quickam.src='/images/header08/tab_quickanswers.jpg'" alt="quickam" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdCaseFiles" valign="top">
                                    <a href="http://www.accessmedicine.com/caseHome.aspx">
                                        <img name="casefiles" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_casefiles.jpg" onmouseover="casefiles.src='/images/header08/tab_casefiles_over.jpg'" onmouseout="casefiles.src='/images/header08/tab_casefiles.jpg'" alt="Case Files" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdPatientEd" valign="top">
                                    <a href="http://www.accessmedicine.com/patientEd.aspx">
                                        <img name="patient" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_patiented.jpg" onmouseover="patient.src='/images/header08/tab_patiented_over.jpg'" onmouseout="patient.src='/images/header08/tab_patiented.jpg'" alt="Patient Education" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdClerkship" valign="top">
                                    <a href="http://www.accessmedicine.com/clerkship.aspx">
                                        <img name="health" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_clerkship.jpg" onmouseover="health.src='/images/header08/tab_clerkship_over.jpg'" onmouseout="health.src='/images/header08/tab_clerkship.jpg'" alt="Custom Clerkship" border="0"></a></td>
		
                                <td id="ctl00_ucheader1_tdCustomCurriculum" valign="top">
                                    <a href="http://www.accessmedicine.com/public/coreCurriculum.aspx" id="ctl00_ucheader1_hypCurric">
                                        <img name="customcurriculum" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_customcurric.jpg" onmouseover="customcurriculum.src='/images/header08/tab_customcurric_over.jpg'" onmouseout="customcurriculum.src='/images/header08/tab_customcurric.jpg'" alt="Custom Curriculum" border="0"></a></td>
		
                                <td style="width: 100%;" valign="top">
                                </td>
                                <td id="ctl00_ucheader1_tdmy" valign="top" width="96">
                                    <a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'/loginPopup.aspx?referURL=myam.aspx',%20true);" id="ctl00_ucheader1_linkMyAM"><img name="my" src="Chapter%2017.%20Breast%20Disorders_archivos/tab_myam.jpg" onmouseover="my.src='/images/header08/tab_myam_over.jpg'" onmouseout="my.src='/images/header08/tab_myam.jpg'" alt="My Saved Images, Bookmarks..." border="0"></a></td>
		
                            </tr>
                        </tbody></table>
                    </td>
                    <td style="width: 30px;">
                    </td>
                </tr>
                <tr height="35" valign="middle">
                    <td colspan="3" align="left" background="Chapter%2017.%20Breast%20Disorders_archivos/tile_search.jpg">
                        <div id="ctl00_ucheader1_RadWindowManager1" style="display: none;">
			<!-- 2009.2.701.20 --><div id="ctl00_ucheader1_RadWindowManager1_alerttemplate" style="display: none;">
		<div class="rwDialogPopup radalert">			
			<div class="rwDialogText">
			{1}				
			</div>
			
			<div>
				<a onclick="$find('{0}').close();" class="rwPopupButton" href="javascript:void(0);">
					<span class="rwOuterSpan">
						<span class="rwInnerSpan">##LOC[OK]##</span>
					</span>
				</a>				
			</div>
		</div>
		</div><div id="ctl00_ucheader1_RadWindowManager1_prompttemplate" style="display: none;">
		 <div class="rwDialogPopup radprompt">			
			    <div class="rwDialogText">
			    {1}				
			    </div>		
			    <div>
				    <script type="text/javascript">
				    function RadWindowprompt_detectenter(id, ev, input)
				    {							
					    if (!ev) ev = window.event;                
					    if (ev.keyCode == 13)
					    {															        
					        var but = input.parentNode.parentNode.getElementsByTagName("A")[0];					        
					        if (but)
						    {							
							    if (but.click) but.click();
							    else if (but.onclick)
							    {
							        but.focus(); var click = but.onclick; but.onclick = null; if (click) click.call(but);							 
							    }
						    }
					       return false;
					    } 
					    else return true;
				    }	 
				    </script>
				    <input onkeydown="return RadWindowprompt_detectenter('{0}', event, this);" class="rwDialogInput" value="{2}" type="text">
			    </div>
			    <div>
				    <a onclick="$find('{0}').close(this.parentNode.parentNode.getElementsByTagName('input')[0].value);" class="rwPopupButton" href="javascript:void(0);"><span class="rwOuterSpan"><span class="rwInnerSpan">##LOC[OK]##</span></span></a>
				    <a onclick="$find('{0}').close(null);" class="rwPopupButton" href="javascript:void(0);"><span class="rwOuterSpan"><span class="rwInnerSpan">##LOC[Cancel]##</span></span></a>
			    </div>
		    </div>				       
		</div><div id="ctl00_ucheader1_RadWindowManager1_confirmtemplate" style="display: none;">
		<div class="rwDialogPopup radconfirm">			
			<div class="rwDialogText">
			{1}				
			</div>						
			<div>
				<a onclick="$find('{0}').close(true);" class="rwPopupButton" href="javascript:void(0);"><span class="rwOuterSpan"><span class="rwInnerSpan">##LOC[OK]##</span></span></a>
				<a onclick="$find('{0}').close(false);" class="rwPopupButton" href="javascript:void(0);"><span class="rwOuterSpan"><span class="rwInnerSpan">##LOC[Cancel]##</span></span></a>
			</div>
		</div>		
		</div><input id="ctl00_ucheader1_RadWindowManager1_ClientState" name="ctl00_ucheader1_RadWindowManager1_ClientState" type="hidden">
		</div>
                        <table class="font10noMargin" border="0" cellpadding="0" cellspacing="0" width="772">
                            <tbody><tr>
                                <td>
                                    <img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" alt="" width="30"></td>
                                <td valign="middle">
                                </td>
                                <td>
                                    <div id="ctl00_ucheader1_RadComboBox2" class="RadComboBox RadComboBox_Default" style="width: 185px; display: inline-block;">
			<table summary="combobox" style="border-width: 0pt;" border="0" cellpadding="0" cellspacing="0">
				<tbody><tr>
					<td class="rcbInputCell rcbInputCellLeft" style="width: 100%;"><input autocomplete="off" class="rcbInput" id="ctl00_ucheader1_RadComboBox2_Input" name="ctl00$ucheader1$RadComboBox2" value="mammography" style="" type="text"></td><td class="rcbArrowCell rcbArrowCellRight rcbArrowCellHidden"><a id="ctl00_ucheader1_RadComboBox2_Arrow" style="overflow: hidden; display: block; position: relative; outline-color: -moz-use-text-color; outline-style: none; outline-width: medium;">select</a></td>
				</tr>
			</tbody></table><div class="rcbSlide" style="z-index: 6000;"><div id="ctl00_ucheader1_RadComboBox2_DropDown" class="RadComboBoxDropDown RadComboBoxDropDown_Default" style="display: none;"><div class="rcbScroll rcbWidth" style="width: 100%;"></div></div></div><input value="{&quot;logEntries&quot;:[],&quot;value&quot;:&quot;&quot;,&quot;text&quot;:&quot;mammography&quot;,&quot;enabled&quot;:true}" autocomplete="off" id="ctl00_ucheader1_RadComboBox2_ClientState" name="ctl00_ucheader1_RadComboBox2_ClientState" type="hidden">
		</div>
                                </td>
                                <td style="padding-left: 10px;" valign="middle">
                                    <div id="ctl00_ucheader1_RadcboSource" class="RadComboBox RadComboBox_Vista" style="width: 200px; display: inline-block;">
			<table summary="combobox" style="border-width: 0pt;" border="0" cellpadding="0" cellspacing="0">
				<tbody><tr class="rcbReadOnly">
					<td class="rcbInputCell rcbInputCellLeft" style="width: 100%;"><input autocomplete="off" class="rcbInput" id="ctl00_ucheader1_RadcboSource_Input" name="ctl00$ucheader1$RadcboSource" value="All AccessMedicine" readonly="readonly" style="" type="text"></td><td class="rcbArrowCell rcbArrowCellRight"><a id="ctl00_ucheader1_RadcboSource_Arrow" style="overflow: hidden; display: block; position: relative; outline-color: -moz-use-text-color; outline-style: none; outline-width: medium;">select</a></td>
				</tr>
			</tbody></table><div class="rcbSlide" style="z-index: 6000;"><div id="ctl00_ucheader1_RadcboSource_DropDown" class="RadComboBoxDropDown RadComboBoxDropDown_Vista" style="display: none;"><div class="rcbScroll rcbWidth" style="width: 100%;"><ul class="rcbList" style="margin: 0pt; padding: 0pt; list-style-type: none; list-style-image: none; list-style-position: outside;"><li class="rcbItem">All AccessMedicine</li><li class="rcbItem">Images, Video, &amp; Audio</li><li class="rcbItem">Drug Monographs</li><li class="rcbItem">Updates</li><li class="rcbItem">Guidelines</li><li class="rcbItem">Quick Answers</li><li class="rcbItem">Harrison's Online</li><li class="rcbItem">CURRENT Medical Diagnosis &amp; Treatment</li><li class="rcbItem">Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</li><li class="rcbItem">Tintinalli's Emergency Medicine</li><li class="rcbItem">Hurst's The Heart</li></ul></div></div></div><input value="{&quot;logEntries&quot;:[],&quot;value&quot;:&quot;0&quot;,&quot;text&quot;:&quot;All AccessMedicine&quot;,&quot;enabled&quot;:true}" autocomplete="off" id="ctl00_ucheader1_RadcboSource_ClientState" name="ctl00_ucheader1_RadcboSource_ClientState" type="hidden">
		</div>
                                    <input id="searchStr" name="searchStr" type="hidden"><input id="sourceStr" name="sourceStr" type="hidden">
                                </td>
                                <td style="padding-left: 10px;" valign="middle">
                                    <a href="javascript:headerDoSearch();">
                                        <img id="go" name="go" src="Chapter%2017.%20Breast%20Disorders_archivos/b_search.gif" alt="Search" border="0"></a></td>
                                <td class="font10noMargin" style="padding-left: 15px;" align="left" valign="middle" width="20">
                                    <a id="ctl00_ucheader1_lnkAutosuggest" class="globalnavsolidNU" href="javascript:__doPostBack('ctl00$ucheader1$lnkAutosuggest','')">Enable Autosuggest</a></td>
                                <td class="font10noMargin" style="padding-left: 15px;" align="left" valign="middle">
                                    <a href="http://www.accessmedicine.com/search/tabAdvSearchAm.aspx?searchstr=mammography" id="ctl00_ucheader1_anchAdvSearch" class="globalnavsolidNU">Advanced<br>
                                        Search</a></td>
                                <td class="font10noMargin" style="padding-left: 15px;" align="left" valign="middle">
                                    <a href="javascript:showAboutSearch('/public/learnMore_search.htm');" id="ctl00_ucheader1_anchAboutSearch" class="globalnavsolidNU">
                                        About<br>
                                        Search</a></td>
                                <td width="100%">
                                    <img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" alt=""></td>
                            </tr>
                        </tbody></table>
                    </td>
                </tr>
            </tbody></table>
            <input name="ctl00$ucheader1$txtPref" id="ctl00_ucheader1_txtPref" value="TRUE" type="hidden">
        </td>
	</tr>
</tbody></table>

</div>
            <div id="contentwrappermaster">
            <div id="contentcolumnmaster">
                    

<style type="text/css">
td.navlinks {font-size: 11px; line-height: 15px; margin-top: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px;}
</style>
		<table border="0" cellpadding="0" cellspacing="0" width="96%">
				<tbody valign="top">
					<tr height="100%" valign="top">
						<td width="100%">
							<table bgcolor="#ffffff" border="0" cellpadding="10" cellspacing="0" height="100%" width="100%">
							    <tbody><tr style="vertical-align: top;">
							        <td style="vertical-align: top;">
							            <table id="ctl00_divMainContentWrapper_tblContent" style="vertical-align: top;" border="0" cellpadding="0" cellspacing="0" width="100%">
	<tbody><tr style="vertical-align: top;">
		<td style="vertical-align: top;">
													<table style="vertical-align: top;" border="0" cellpadding="0" cellspacing="0" width="100%">
														<tbody><tr>
															<td class="font11noMargin"><a class="NU" href="javascript:history.back();">&lt; Back</a></td>
														</tr>
													</tbody></table>
													<br class="Spacer5">
													<table style="border-top: 1px solid rgb(153, 153, 153); border-bottom: 1px solid rgb(153, 153, 153);" border="0" cellpadding="0" cellspacing="0" width="100%">
														<tbody><tr>
															<td>
																<table style="border-top: 1px solid rgb(255, 255, 255); border-bottom: 1px solid rgb(255, 255, 255);" bgcolor="#d1d8de" border="0" cellpadding="5" cellspacing="0" width="100%">
																	<tbody><tr>
																		<td>
																			<table border="0" cellpadding="0" cellspacing="0" width="100%">
																				<tbody><tr>
																					<td valign="top"><span id="ctl00_divMainContentWrapper_lblBookCoverImage"><img src="Chapter%2017.%20Breast%20Disorders_archivos/covermed_cmdt.gif" border="0"></span></td>
																					<td><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="5"></td>
																					<td class="font11noMargin" width="100%"><span id="ctl00_divMainContentWrapper_lblChapterLinks"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="breadcrumbs"><a href="http://www.accessmedicine.com/resourceTOC.aspx?resourceID=1" class="solid"><b>CURRENT Medical Dx &amp; Tx</b></a>&nbsp;&gt;<br><br class="Spacer5"><font class="chapterTitle"><b>Chapter 17. Breast Disorders</b></font></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" border="0" width="10"></td></tr></tbody></table><br class="Spacer5"><link rel="stylesheet" href="Chapter%2017.%20Breast%20Disorders_archivos/Global.css" type="text/css" media="screen" title="LMS main style sheet" xmlns:mbp="http://apache.org" xmlns:idx="http://www.w3.org" xmlns:msxml="urn:schemas-microsoft-com:xslt"><a name="8538"></a><table xmlns:mbp="http://apache.org" xmlns:idx="http://www.w3.org" xmlns:msxml="urn:schemas-microsoft-com:xslt" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td valign="top" width="100%">
	<font class="font11">Armando E. Giuliano, MD,&nbsp;Sara A. Hurvitz, MD</font></td></tr></tbody></table></span></td>
																																									
																					<!--<td id="ctl00_divMainContentWrapper_tdViewAuthors" class="font11noMargin" align="right" valign="top"><a class="NU" href="javascript:windowReference('','authors.aspx?aID=8612');">View&nbsp;Author&nbsp;Info</a></td>
		-->
																				</tr>
																			</tbody></table>
																		</td>
																	</tr>
																</tbody></table>
															</td>
														</tr>
													</tbody></table>
													<table border="0" cellpadding="0" cellspacing="0" width="100%">
														<tbody><tr>
															<td id="ctl00_divMainContentWrapper_tdChapterNavigation" valign="top" width="250">
																<table style="border-left: 1px solid rgb(153, 153, 153); border-right: 1px solid rgb(153, 153, 153);" border="0" cellpadding="5" cellspacing="0" width="250">
																	<tbody><tr id="ctl00_divMainContentWrapper_trSections">
			<td class="font11noMargin" bgcolor="#d1d8de">
																			<b>Sections in this chapter:</b><br>
																			<span id="ctl00_divMainContentWrapper_lblSections"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="0"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><img src="Chapter%2017.%20Breast%20Disorders_archivos/bullet_ql.gif" align="absmiddle" border="0"><a style="text-decoration: none; color: rgb(51, 51, 51);"><b>Benign Breast Disorders</b></a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><a href="http://www.accessmedicine.com/content.aspx?aID=8540">Fibrocystic Condition</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><a href="http://www.accessmedicine.com/content.aspx?aID=8562">Fibroadenoma of the Breast</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><a href="http://www.accessmedicine.com/content.aspx?aID=8567">Nipple Discharge</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><a href="http://www.accessmedicine.com/content.aspx?aID=8583">Fat Necrosis</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><a href="http://www.accessmedicine.com/content.aspx?aID=8585">Breast Abscess</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><a href="http://www.accessmedicine.com/content.aspx?aID=8588">Disorders of the Augmented Breast</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="0"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><img src="Chapter%2017.%20Breast%20Disorders_archivos/bullet_ql.gif" align="absmiddle" border="0"><b><font color="#990000">Carcinoma of the Female Breast</font></b></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td width="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="0"></td><td class="quickLinkNav" width="100%"><br class="Spacer5"><img src="Chapter%2017.%20Breast%20Disorders_archivos/bullet_ql.gif" align="absmiddle" border="0"><a href="http://www.accessmedicine.com/content.aspx?aID=8764">Carcinoma of the Male Breast</a></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="quickLinkNav" width="0"><br><a href="javascript:windowReference('Print','popup.aspx?aID=8592&amp;print=yes_chapter');" class="navlinks" style="text-decoration: none; white-space: nowrap;"><b>View/Print Entire Chapter</b> </a></td></tr></tbody></table><br class="Spacer10"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="1" width="10"></td></tr></tbody></table></span>
																			
																			<br class="Spacer5">
																		</td>
		</tr>
		
																	<tr id="ctl00_divMainContentWrapper_trSeeAlso">
			<td class="font11noMargin" bgcolor="#ffcc66">
																			<b>SEE ALSO</b> on AccessMedicine<br>
																			<br class="Spacer5">
																			<span id="ctl00_divMainContentWrapper_lblRelated"> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=adjuvant+chemotherapy&amp;rootID=12810">adjuvant chemotherapy</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=bevacizumab&amp;rootID=36019">bevacizumab</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=bilateral+breast+cancer&amp;rootID=35624">bilateral breast cancer</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=biopsy+of+breast&amp;rootID=41301">biopsy of breast</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=biopsy%2c+needle&amp;rootID=15298">biopsy, needle</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=brca2+gene&amp;rootID=20010">brca2 gene</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+biopsy%2c+needle&amp;rootID=48324">breast biopsy, needle</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+cancer&amp;rootID=33482">breast cancer</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+cancer+and+pregnancy&amp;rootID=12100">breast cancer and pregnancy</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+cancer+metastatic&amp;rootID=12101">breast cancer metastatic</a><br><a id="lnkMore" href="#trSeeAlso" onclick="javascript:this.style.display='none';toggleBlock('spanSeeAlsoToggle');"><b>more...</b></a><span id="spanSeeAlsoToggle" style="display: none;"> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+diseases&amp;rootID=15555">breast diseases</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+mass&amp;rootID=12102">breast mass</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+neoplasm+screening&amp;rootID=47008">breast neoplasm screening</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=breast+self-examination&amp;rootID=15560">breast self-examination</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=cancer+survivorship&amp;rootID=47818">cancer survivorship</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=chemotherapy+regimen&amp;rootID=12198">chemotherapy regimen</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=cyclophosphamide&amp;rootID=12452">cyclophosphamide</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=diphosphonates&amp;rootID=11983">diphosphonates</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=doxorubicin&amp;rootID=8348">doxorubicin</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=drug+delivery%2c+targeted&amp;rootID=50623">drug delivery, targeted</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=ductal+carcinoma+in+situ&amp;rootID=12571">ductal carcinoma in situ</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=edema&amp;rootID=9035">edema</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=excisional+biopsy+of+breast+with+preoperative+localization&amp;rootID=45721">excisional biopsy of breast with preoperative localization</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=fine+needle+aspiration+biopsy+for+cytology&amp;rootID=13002">fine needle aspiration biopsy for cytology</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=genes%2c+brca1&amp;rootID=20009">genes, brca1</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=hormone+receptor&amp;rootID=13243">hormone receptor</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=hormone+therapy&amp;rootID=13240">hormone therapy</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=inflammatory+breast+cancer&amp;rootID=33672">inflammatory breast cancer</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=lapatinib&amp;rootID=52932">lapatinib</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=lobular+carcinoma+in+situ&amp;rootID=33471">lobular carcinoma in situ</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=mammaplasty&amp;rootID=23117">mammaplasty</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=mammography&amp;rootID=23122">mammography</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=mastectomy%2c+segmental&amp;rootID=23223">mastectomy, segmental</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=mastitis&amp;rootID=23230">mastitis</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=modified+radical+mastectomy&amp;rootID=23221">modified radical mastectomy</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=neoadjuvant+therapy&amp;rootID=24429">neoadjuvant therapy</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=nipple+discharge&amp;rootID=33606">nipple discharge</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=ovariectomy&amp;rootID=25367">ovariectomy</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=paclitaxel&amp;rootID=233">paclitaxel</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=paget%27s+disease%2c+mammary&amp;rootID=25450">paget's disease, mammary</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=radiation&amp;rootID=27455">radiation</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=receptor%2c+erbb-2&amp;rootID=27607">receptor, erbb-2</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=tamoxifen&amp;rootID=29771">tamoxifen</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=trastuzumab&amp;rootID=9616">trastuzumab</a><br> - <a href="http://www.accessmedicine.com/search/searchAMResult.aspx?searchType=1&amp;rootTerm=ultrasonography&amp;rootID=9213">ultrasonography</a><br></span></span>
																		</td>
		</tr>
		
																</tbody></table>
																<br class="Spacer10">
															</td>
		
															<td valign="top">
																<br class="Spacer10">
																<table border="0" cellpadding="0" cellspacing="0" width="100%">
																	<tbody><tr>
																		<td style="height: 18px;"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td>
																		
																		<td style="height: 18px;" align="right" width="100%">
																			<script language="JavaScript">
																	            MM_preloadImages('images/newb_print_over.gif','images/newb_email_over.gif','images/newb_bookmark_over.gif','images/newb_pda_over.gif','images/page_previous_over.gif','images/page_next_over.gif');
																			</script>																			
																			<a href="javascript:windowNonResizable('citeThis',500,250,'citepopup.aspx?aid=8538&amp;citeType=1',%20true);" id="ctl00_divMainContentWrapper_hrefCiteTop"><img src="Chapter%2017.%20Breast%20Disorders_archivos/newb_howtocite.gif" id="ctl00_divMainContentWrapper_imgCiteTop" border="0"></a>&nbsp;<a href="javascript:windowReference('Print','popup.aspx?aID=8592&amp;print=yes');" id="ctl00_divMainContentWrapper_hrefPrintSectionTop"><img name="print" src="Chapter%2017.%20Breast%20Disorders_archivos/newb_printsection.gif" onmouseover="print.src='images/newb_printsection_over.gif';" onmouseout="print.src='images/newb_printsection.gif';" border="0"></a>&nbsp;<a href="javascript:windowReference('Print','popup.aspx?aID=8592&amp;print=yes_chapter');" id="ctl00_divMainContentWrapper_hrefPrintChapterTop"><img name="print" src="Chapter%2017.%20Breast%20Disorders_archivos/newb_printchapter.gif" onmouseover="print.src='images/newb_printchapter_over.gif';" onmouseout="print.src='images/newb_printchapter.gif';" border="0"></a>&nbsp;<a href="javascript:windowReference('Print','emailtocolleague.aspx?topicTitle=Carcinoma+of+the+Female+Breast&amp;aID=8612',true);" onmouseover="email.src='images/newb_email_over.gif';" onmouseout="email.src='images/newb_email.gif';"><img name="email" src="Chapter%2017.%20Breast%20Disorders_archivos/newb_email.gif" border="0"></a>&nbsp;<a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);"><img src="Chapter%2017.%20Breast%20Disorders_archivos/newb_bookmark.gif" id="ctl00_divMainContentWrapper_imgBookmark" name="bookmark" border="0"></a>&nbsp;<a href="javascript:windowReference('','/pdaDownload.aspx?aid=8592');"><img src="Chapter%2017.%20Breast%20Disorders_archivos/newb_pda.gif" id="ctl00_divMainContentWrapper_pda1" name="pda1" onmouseover="pda1.src='images/newb_pda_over.gif';" onmouseout="pda1.src='images/newb_pda.gif';" border="0"></a>
																		</td>
																	</tr>
																</tbody></table>																																
																<br class="Spacer10">
																<table id="ctl00_divMainContentWrapper_tblSectionNavigationTop" border="0" cellpadding="0" cellspacing="0" width="100%">
			<tbody><tr>
				<td><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td>
				<td class="navlinks" align="center" width="100%"><a id="ctl00_divMainContentWrapper_lnkPreviousTop" href="http://www.accessmedicine.com/content.aspx?aID=8588"><font class="font12noMargin">&lt;</font>&nbsp;<b>Previous 
																					Section</b></a>&nbsp;<font color="#999999">|</font>&nbsp;<a id="ctl00_divMainContentWrapper_lnkNextTop" href="http://www.accessmedicine.com/content.aspx?aID=8764"><b>Next 
																					Section</b>&nbsp;<font class="font12noMargin">&gt;</font></a></td>
			</tr>
		</tbody></table>
		
																<br class="Spacer10">
																<table border="0" cellpadding="0" cellspacing="0" width="100%">
																	<tbody><tr>
																		<td><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td>
																		<td width="100%">
																		    
																			
																			<span id="ctl00_divMainContentWrapper_lblSectionTitle" class="contentHead1"><p class="contentHead1">Carcinoma of the Female Breast</p></span>
																			
																			
																			
																			<span id="ctl00_divMainContentWrapper_lblContent"><link rel="stylesheet" href="Chapter%2017.%20Breast%20Disorders_archivos/Global.css" type="text/css" media="screen" title="LMS main style sheet" xmlns:mbp="http://apache.org" xmlns:idx="http://www.w3.org" xmlns:msxml="urn:schemas-microsoft-com:xslt"><a name="8592"></a><table xmlns:mbp="http://apache.org" xmlns:idx="http://www.w3.org" xmlns:msxml="urn:schemas-microsoft-com:xslt" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td bgcolor="#ffffff" valign="top" width="100%">
		<a name="8593"></a>
			<p class="contentHead5">Essentials of Diagnosis</p>
			<ul><li class="font12List">Most women with breast cancer do not have identifiable risk factors. </li><li class="font12List">Risk factors include delayed childbearing, positive family 
history of breast cancer or genetic mutations <i>(BRCA1, BRCA2),</i> and 
personal history of breast cancer or some types of proliferative 
conditions. </li><li class="font12List"><i><b>Early findings:</b></i> Single, nontender, firm to hard mass with ill-defined margins; mammographic abnormalities and no palpable mass. </li><li class="font12List"><i><b>Later findings:</b></i>
Skin or nipple retraction; axillary lymphadenopathy; breast
enlargement, erythema, edema, pain; fixation of mass to skin or chest
wall. </li></ul>
		<a name="8598"></a>
			<p class="contentHead5">Incidence &amp; Risk Factors</p><a name="8599"></a><p class="contentBody">Breast cancer will develop in one of eight American women. Next 
to skin cancer, breast cancer is the most common cancer in women; 
it is second only to lung cancer as a cause of death. The probability 
of developing breast cancer increases throughout life. The mean 
age and the median age of women with breast cancer is 61 years.</p><a name="8600"></a><p class="contentBody">
In 2009, there were approximately 192,370 new cases of breast cancer
and 40,170 deaths from this disease in women in the United States. An
additional 62,280 cases of breast carcinoma in situ were detected,
principally by screening <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>.
The incidence of breast cancer has slightly decreased over time,
possibly because of decreased use of postmenopausal hormone replacement
therapy. Mortality has also decreased slightly due to early detection
and increased use of systemic therapy.</p><a name="776317"></a><p class="contentBody">Although more than 75% of women in whom breast cancer 
has been diagnosed do not have an obvious risk factor, there are 
several that play a role in breast cancer development. Breast cancer 
is three to four times more likely to develop in women with a first-degree 
relative (mother, daughter, or sister) who had breast cancer than 
in those without a family history. Risk is further increased in 
patients whose mothers' or sisters' breast cancers 
occurred before menopause or were bilateral and in those with a family 
history of breast cancer in two or more first-degree relatives as 
well as in women of Ashkenazi Jewish descent. Nulliparous women 
and women whose first full-term pregnancy was after age 35 have 
a 1.5 times higher incidence of breast cancer than multiparous women. 
Late menarche and artificial menopause are associated with a lower 
incidence, whereas early menarche (under age 12) and late natural 
menopause (after age 50) are associated with a slight increase in 
risk. Fibrocystic condition, when accompanied by proliferative changes, 
papillomatosis, or atypical epithelial hyperplasia, and increased 
breast density on mammogram are also associated with an increased 
incidence. A woman who had cancer in one breast is at increased 
risk for cancer developing in the other breast. In these women, 
a contralateral cancer develops at the rate of 1% or 2% per 
year. Women with cancer of the uterine corpus have a risk of breast 
cancer significantly higher than that of the general population, 
and women with breast cancer have a comparably increased risk for endometrial 
cancer. In the United States, breast cancer is more common in white 
women. The incidence of the disease among nonwhite (mostly black) women 
is increasing, especially in younger women. In general, rates reported 
from developing countries are low, whereas rates are high in developed 
countries, with the notable exception of Japan. Some of the variability 
may be due to underreporting in the developing countries, but a 
real difference probably exists. Dietary factors, particularly increased 
fat consumption, may account for some differences in incidence. 
Oral contraceptives do not appear to increase the risk of breast 
cancer. There is evidence that administration of estrogens to postmenopausal women 
may result in a slightly increased risk of breast cancer, but only 
with higher, long-term doses of estrogens. Concomitant administration 
of <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6847');">progesterone</a> and estrogen may markedly increase the incidence 
of breast cancer compared with the use of estrogen alone. The Women's 
Health Initiative prospective randomized study of <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1510');">hormone</a> replacement 
therapy stopped treatment with estrogen and progesterone early because 
of an increased risk of breast cancer compared with untreated controls 
or women treated with estrogen alone. With decreasing use of these 
hormones, breast cancer rates may continue to decrease. Alcohol 
consumption increases the risk very slightly. </p><a name="3175501"></a><p class="contentBody">Some inherited breast cancers have been found to be associated 
with a gene on chromosome 17. This gene, <i>BRCA1</i>, 
is mutated in families with early-onset breast and ovarian cancer. 
Breast cancer will develop in approximately 85% of women 
with <i>BRCA1 </i>gene mutations during their 
lifetime. Other genes are associated with increased risk of breast and 
other cancers, such as <i>BRCA2</i> (associated 
with a gene on chromosome 13); ataxia-telangiectasia mutation; and 
mutation of <i>p53</i>, the tumor suppressor gene. 
Mutations to <i>p53</i> have been found in 
approximately 1% of breast cancers in women under 40 years 
of age. Genetic testing is commercially available for women at high 
risk for breast cancer. Women with genetic mutations in whom breast 
cancer develops may be treated in the same way as women who do not 
have mutations (ie, lumpectomy), though there is an increased ipsilateral 
and contralateral recurrence rate after lumpectomy for these women. 
Such women with mutations often elect bilateral mastectomy as treatment. 
Some states have enacted legislation to prevent insurance companies 
from considering mutations as "preexisting conditions," preventing 
insurability.</p><a name="8601"></a><p class="contentBody">
				Women at greater than normal risk for developing 
breast cancer (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8602');">Table 17–1</a>) should be identified by their 
practitionersand monitored carefully. Those with an exceptional family history 
should be counseled about the option of genetic testing. Some of 
these high-risk women may consider prophylactic mastectomy, oophorectomy, 
or <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">tamoxifen</a>, an FDA-approved preventive agent.</p><table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8602');" border="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_table.gif" border="0"></a></td><td class="font11" align="left" valign="middle"><b><a href="javascript:windowReference('Reference','popup.aspx?aID=8602');"><b><font class="font12">Table 17–1.&nbsp;Factors associated 
with increased risk of breast cancer.
					</font></b></a></b></td></tr></tbody></table><a name="776318"></a>
			<p class="contentHead5">Prevention</p><a name="8603"></a><p class="contentBody">The National Surgical Adjuvant Breast Project (NSABP) conducted 
the first Breast Cancer Prevention Trial (BCPT) P-1, which evaluated 
<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">tamoxifen</a> as a preventive agent in women with no personal history of 
breast cancer but at high risk for developing the disease. Women 
who received tamoxifen for 5 years had about a 50% reduction 
in noninvasive and invasive cancers compared with women taking placebo. However, 
women over age 50 who received the drug had an increased incidence 
of endometrial cancer and deep venous thrombosis. Unfortunately, 
no survival data will be produced from this trial because it was 
stopped. </p><a name="775867"></a><p class="contentBody">The <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1671');">selective estrogen receptor modulator (SERM)</a>&nbsp;<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6895');">raloxifene</a>, 
effective in preventing osteoporosis, is also effective in preventing 
breast cancer. The initial study, Multiple Outcomes of Raloxifene 
Evaluations (MORE) trial, aimed at determining the effect of raloxifene 
on bone, demonstrated that raloxifene also reduced breast cancer risk 
in women being given the drug. After 8 years, raloxifene demonstrated 
an overall reduction of invasive breast cancer of 66%. 
Because this study was designed to determine the effect of raloxifene 
on bone density, it was conducted in women at lower risk for breast 
cancer. To better understand the preventive effect of raloxifene 
in the high-risk population, a randomized study comparing raloxifene 
with <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">tamoxifen</a> was conducted. </p><a name="775868"></a><p class="contentBody">The Study of <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">Tamoxifen</a> and <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6895');">Raloxifene</a> (STAR) P-2 trial, conducted 
by the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
and completed in 2006, demonstrated that raloxifene and tamoxifen 
are equivalent in preventing invasive breast cancer in the high-risk 
population. Many of the side effects of raloxifene are the same 
as tamoxifen with a slight decrease in cataracts and thromboembolic 
events in the raloxifene group. Surprisingly, noninvasive cancer 
(DCIS) occurred more commonly in women treated with raloxifene. </p><a name="775869"></a><p class="contentBody">Similar to SERMs, aromatase inhibitors (<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=35591');">AI</a>)
have shown great success in treating breast cancer with fewer side
effects, although bone loss is a significant side effect of this
long-term treatment. Several large multicenter studies (eg,
International Breast Cancer Intervention Study II [IBIS-II] and
National Cancer Institute of Canada Clinical Trials Group [NCIC CTG]
are underway to determine whether AIs have a role in preventing breast
cancer. </p><a name="775870"></a><p class="contentBody">In addition to pharmaceutical therapy, patients continue to seek 
a way to prevent breast cancer. There has been considerable research 
on incorporating diet and exercise into the lifestyle of women who 
may be at risk for cancer. The Women's Intervention Nutrition 
Study was conducted to determine whether decreasing dietary fat 
intake would reduce the incidence of breast cancer recurrence after 
initial treatment. Although the trial demonstrated a decrease in 
recurrence in the follow-up period, it did not reach statistical 
significance.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top">Boyd NF et al. Mammographic density and the risk and detection 
of breast cancer. N Engl J Med. 2007 Jan 18;356(3):227–36.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17229950&amp;dopt=Abstract" target="new">[PMID: 
17229950]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Chan K et al. Chemoprevention of breast cancer for women at high 
risk. Semin Oncol. 2006 Dec;33(6):642–6. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17145342&amp;dopt=Abstract" target="new">[PMID: 17145342]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Graeser
MK et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation
carriers. J Clin Oncol. 2009 Dec 10;27(35):5887–92. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19858402&amp;dopt=Abstract" target="new">[PMID: 
19858402]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178676"></a>Jemal A et al. Cancer Statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225–49.  
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19474385&amp;dopt=Abstract" target="new">[PMID: 19474385]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Jordan VC. Chemoprevention of breast cancer with selective estrogen-receptor 
modulators. Nat Rev Cancer. 2007 Jan;7(1):46–53. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17186017&amp;dopt=Abstract" target="new">[PMID: 
17186017]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Kellen E et al. Lifestyle changes and breast cancer prognosis: a review. Breast Cancer Res Treat. 2009 Mar;114(1):13–22. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18389367&amp;dopt=Abstract" target="new">[PMID: 18389367]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Linos E et al. Diet and breast cancer. Curr Oncol Rep. 2007 Jan;9(1):31–41. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17164045&amp;dopt=Abstract" target="new">[PMID: 
17164045]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Lynch HT et al. Hereditary breast cancer: part I. Diagnosing hereditary 
breast cancer syndromes. Breast J. 2008 Jan–Feb;14(1):3–13.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18086272&amp;dopt=Abstract" target="new">[PMID: 
18086272]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952935"></a>Nelson
HD et al. Systematic review: comparative effectiveness of medications
to reduce risk for primary breast cancer. Ann Intern Med. 2009 Nov
17;151(10):703–15, W-226-35. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19920271&amp;dopt=Abstract" target="new">[PMID: 19920271]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Newman LA et al. Breast cancer risk assessment and risk reduction. 
Surg Clin North Am. 2007 Apr;87(2):307–16. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17498528&amp;dopt=Abstract" target="new">[PMID: 
17498528]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Patel RR et al. Optimizing the antihormonal treatment and prevention 
of breast cancer. Breast Cancer. 2007;14(2):113–22. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17485895&amp;dopt=Abstract" target="new">[PMID: 
17485895]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952936"></a>Pierce
JP et al. Influence of a diet very high in vegetables, fruit, and fiber
and low in fat on prognosis following treatment for breast cancer: the
Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007
Jul 18;298(3):289–98. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17635889&amp;dopt=Abstract" target="new">[PMID: 17635889]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Prentice
RL et al. Low-fat dietary pattern and cancer incidence in the women’s
health initiative dietary modification randomized controlled trial. J
Natl Cancer Inst. 2007 Oct 17;99(20):1534–43. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17925539&amp;dopt=Abstract" target="new">[PMID: 
17925539]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Pruthi S et al. A multidisciplinary approach to the management of 
breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc. 
2007 Aug;82(8):999–1012.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17673070&amp;dopt=Abstract" target="new">[PMID: 
17673070]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952937"></a>Visvanathan
K et al. American Society of Clinical Oncology clinical practice
guideline update on the use of pharmacologic interventions including
tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk
reduction. J Clin Oncol. 2009 Jul 1;27(19):3235–58. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19470930&amp;dopt=Abstract" target="new">[PMID: 19470930]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Vogel VG et al. The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009 Jan;9(1):51–60. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19105706&amp;dopt=Abstract" target="new">[PMID: 
19105706]</a><br><br class="Spacer10"></td></tr></tbody></table><a name="8604"></a>
			<p class="contentHead5">Early Detection of Breast Cancer</p><a name="8605"></a>
				<p class="contentHead8">Screening Programs</p><a name="8606"></a><p class="contentBody"><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=560521');"><b>See Related Guideline from <i>CURRENT Practice Guidelines in Primary Care 2009</i></b>
					</a></p><p class="contentBody">There have been a 
number of large screening programs conducted over the years. Such 
programs, consisting of physical and mammographic examination of 
asymptomatic women, identify about 10 cancers per 1000 women over 
the age of 50 and about 2 cancers per 1000 women under the age of 
50. These studies show the increased survival benefit of screening 
programs, as screening detects cancer before it has spread to the lymph 
nodes in about 80% of the women evaluated. This increases 
the chance of survival to about 85% at 5 years.</p><a name="8607"></a><p class="contentBody">
					Both physical examination and <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> are necessary for maximum 
yield in screening programs, since about 35–50% of 
early breast cancers can be discovered only by <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> and another 
40% can be detected only by palpation. About 
one-third of the abnormalities detected on screening mammograms 
will be found to be malignant when biopsy is performed. The probability 
of cancer on a screening mammogram is directly related to the Breast 
Imaging and Reporting Data System (BIRADS) assessment, and work-up should 
be performed based on this classification. Women 20–40 
years of age should have a breast examination as part of routine 
medical care every 2–3 years. Women over age 40 years should 
have annual breast examinations. The sensitivity of <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> 
varies from approximately 60% to 90%. This sensitivity 
depends on several factors, including patient age (breast density) 
and tumor size, location, and mammographic appearance. In young 
women with dense breasts <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23505');">(see x-ray)</a>, <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> is less sensitive than in 
older women with fatty breasts, in whom <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> can detect at 
least 90% of malignancies <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23504');">(see x-ray)</a>. Smaller tumors, particularly 
those without calcifications, are more difficult to detect, especially 
in dense breasts. The lack of sensitivity and the low incidence 
of breast cancer in young women have led to questions concerning 
the value of <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> for screening in women 40–50 years 
of age. The specificity of <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> in women under 50 years varies 
from about 30% to 40% for nonpalpable mammographic 
abnormalities to 85% to 90% for clinically evident 
malignancies.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23504');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_008.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23504');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23504');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Fatty breast. (Courtesy of K Kerlikowske.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23505');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_009.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23505');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23505');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Extremely dense breast. (Courtesy of K Kerlikowske.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8608"></a><p class="contentBody">Screening recommendations for women in their 40s are based, in 
part, on trials from Sweden. Two trials showed a statistical advantage 
for screening women in their 40s, and a meta-analysis similarly revealed 
a statistical survival advantage for screened women with longer 
follow-up. The National Cancer Advisory Board recommended that women 
in their 40s with average risk factors have screening <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> 
every 1–2 years and that women at higher risk seek medical 
advice on when to begin screening. Studies continue to support the 
value of screening <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> in women over 40 years (see <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=60');">Table 
1–6</a>). Such women should have annual <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> and physical 
examination. </p><a name="8609"></a><p class="contentBody">The beneficial effect of screening in women aged 50–69 
years is undisputed and has been confirmed by all clinical trials. 
The efficacy of screening in older women—those older than 
70 years—is inconclusive and is difficult to determine 
because few studies have examined this population.</p><a name="8610"></a>
				<p class="contentHead8">Self-Examination</p><a name="8611"></a><p class="contentBody">Breast self-exam (BSE) has not been shown to improve survival. 
Because of the lack of strong evidence demonstrating value, the 
American Cancer Society no longer recommends monthly BSE beginning 
at age 20 years. The recommendation is that patients be made aware 
of the potential benefits, limitations, and harms (increased biopsies 
or false-positive results) associated with BSE. Women who choose 
to perform BSE should be advised regarding the proper technique. 
Premenopausal women should perform the examination 7–8 
days after the start of the menstrual period. First, breasts should 
be inspected before a mirror with the hands at the sides, overhead, 
and pressed firmly on the hips to contract the pectoralis muscles 
causing masses, asymmetry of breasts, and slight dimpling of the 
skin to become apparent. Next, in a supine position, each breast should 
be carefully palpated with the fingers of the opposite hand. Some 
women discover small breast lumps more readily when their skin is 
moist while bathing or showering. While BSE is not a recommended 
practice, patients should recognize and report any breast changes 
to their practitioners as it remains an important facet of proactive 
care.</p><a name="8612"></a>
				<p class="contentHead8">Imaging</p><a name="8613"></a><p class="contentBody">Mammography is the most reliable means of detecting breast cancer 
before a mass can be palpated. Slowly growing cancers can be identified 
by <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> at least 2 years before reaching a size detectable 
by palpation. Film screen 
<font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> delivers &lt; 0.4 cGy to the mid breast per view. 
Although full-field digital <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> provides an easier method 
to maintain and review mammograms, it has not been proven that it 
provides better images or increases detection rates more than film 
<font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>. In subset analysis of a large study, digital <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> 
seemed slightly superior in women with dense breasts. Computer-assisted 
detection (CAD) has not shown any increase in detection of cancers and 
is not routinely performed at centers with experienced mammographers.</p><a name="8614"></a><p class="contentBody">Calcifications are the most easily recognized mammographic abnormality. 
The most common findings associated with carcinoma of the breast 
are clustered polymorphic microcalcifications. Such calcifications 
are usually at least five to eight in number, aggregated in one 
part of the breast and differing from each other in size and shape, 
often including branched or V- or Y-shaped configurations. There 
may be an associated mammographic mass density or, at times, only 
a mass density with no calcifications. Such a density usually has 
irregular or ill-defined borders and may lead to architectural distortion 
within the breast <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23506');">(see x-ray)</a> but may be subtle and difficult to detect.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23506');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_005.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23506');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23506');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Cancer in a fatty breast. (Courtesy of K Kerlikowske.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8616"></a><p class="contentBody">Indications for <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> are as follows: (1) to screen at 
regular intervals asymptomatic women at high risk for developing breast cancer 
(see above); (2) to evaluate each breast when a diagnosis of potentially 
curable breast cancer has been made, and at yearly intervals thereafter; 
(3) to evaluate a questionable or ill-defined breast mass or other 
suspicious change in the breast; (4) to search for an occult breast 
cancer in a woman with metastatic disease in axillary nodes or elsewhere 
from an unknown primary; (5) to screen women prior to cosmetic operations 
or prior to biopsy of a mass, to examine for an unsuspected cancer; 
(6) to monitor those women with breast cancer who have been treated 
with breast-conserving surgery and radiation; and (7) to monitor 
the contralateral breast in those women with breast cancer treated 
with mastectomy.</p><a name="8617"></a><p class="contentBody">Patients with a dominant or suspicious mass must undergo biopsy 
despite mammographic findings. The mammogram should be obtained 
prior to biopsy so that other suspicious areas can be noted and 
the contralateral breast can be evaluated. <font color="#990000"><b><a name="searchTerm"></a>Mammography</b></font> is never 
a substitute for biopsy because it may not reveal clinical cancer, 
especially in a very dense breast, as may be seen in young women 
with fibrocystic changes, and may not reveal medullary cancers <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23507');">(see x-ray)</a>.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23507');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_003.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23507');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23507');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Heterogeneously dense tissue. (Courtesy of K Kerlikowske.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8618"></a><p class="contentBody">Communication and documentation among the patient, the referring 
practitioner, and the interpreting physician are critical for high-quality 
screening and diagnostic <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>. The patient should be told 
about <i>how</i> she will receive timely results 
of her mammogram; that <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> does not "rule out" cancer; 
and that she may receive a correlative examination such as ultrasound 
at the <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> facility if referred for a suspicious lesion. 
She should also be aware of the technique and need for breast compression 
and that this may be uncomfortable. The <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> facility should 
be informed <i>in writing by the clinician</i> of 
abnormal physical examination findings. The Agency for Health Care 
Policy and Research (AHCPR) Clinical Practice Guidelines strongly 
recommend that all <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> reports be communicated in writing 
to the patient and referring practitioner. MRI and ultrasound may 
be useful screening modalities in women who are at high risk for 
breast cancer but not for the general population. The sensitivity 
of MRI is much higher than <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>; however, the specificity is 
significantly lower and this results in multiple unnecessary biopsies. 
The increased sensitivity despite decreased specificity may be considered 
a reasonable trade-off for those at increased risk for developing 
breast cancer but not for normal-risk population. MRI is useful 
in women with breast implants to determine the character of a lesion 
present in the breast and to search for implant rupture and at times 
is helpful in patients with prior lumpectomy and radiation. In addition, 
positron emission tomography (PET) may play a role in imaging atypical 
lesions but is less sensitive for early breast cancer than is MRI 
or <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>. The primary role remains evaluation of metastatic 
deposits.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top"><a name="3178677"></a>Armstrong K et al. Screening <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> in women 
40 to 49 years of age: a systematic review for the American College 
of Physicians. Ann Intern Med. 2007 Apr 3;146(7):516–26. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17404354&amp;dopt=Abstract" target="new">[PMID: 
17404354]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178678"></a>Berstad P et al. Alcohol intake and breast cancer risk among young women. Breast Cancer Res Treat. 2008 Mar;108(1):113–20. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17468952&amp;dopt=Abstract" target="new">[PMID: 17468952]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178679"></a>Budakoglu II et al. The effectiveness of training for breast 
cancer and breast self-examination in women aged 40 and over. J Cancer 
Educ. 2007 Summer;22(2):108–11. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17605625&amp;dopt=Abstract" target="new">[PMID: 17605625]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178680"></a>Feig SA. Screening <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>: a successful public health initiative. 
Rev Panam Salud Publica. 2006 Aug–Sep;20(2-3):125–33. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17199907&amp;dopt=Abstract" target="new">[PMID: 
17199907]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952938"></a>Houssami
N et al. Accuracy and surgical impact of magnetic resonance imaging in
breast cancer staging: systematic review and meta-analysis in detection
of multifocal and multicentric cancer. J Clin Oncol. 2008 Jul
1;26(19):3248–58. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18474876&amp;dopt=Abstract" target="new">[PMID: 18474876]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952939"></a>Jackson SL et al. Variability of interpretive accuracy among diagnostic <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> facilities. J Natl Cancer Inst. 2009 Jun 3;101(11):814–27. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19470953&amp;dopt=Abstract" target="new">[PMID: 19470953]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952940"></a>Karellas A et al. Breast cancer imaging: a perspective for the next decade. Med Phys. 2008 Nov;35(11):4878–97. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19070222&amp;dopt=Abstract" target="new">[PMID: 19070222]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178681"></a>Knutson D et al. Screening for breast cancer: current recommendations 
and future directions. Am Fam Physician. 2007 Jun 1;75(11):1660–6. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17575656&amp;dopt=Abstract" target="new">[PMID: 
17575656]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178683"></a>Le-Petross CH et al. Evolving role of imaging modalities in inflammatory breast cancer. Semin Oncol. 2008 Feb;35(1):51–63. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18308146&amp;dopt=Abstract" target="new">[PMID: 18308146]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178684"></a>Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am. 2007 Sep;45(5):863–80.  
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17888774&amp;dopt=Abstract" target="new">[PMID: 17888774]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178685"></a>Murphy
CD et al. The American Cancer Society guidelines for breast screening
with magnetic resonance imaging: an argument for genetic testing.
Cancer. 2008 Dec 1;113(11):3116–20. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18932252&amp;dopt=Abstract" target="new">[PMID: 18932252]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178686"></a>Van Ongeval Ch. Digital <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> for screening and diagnosis of breast cancer: an overview. JBR-BTR. 2007 May–Jun;90(3):163–6.  
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17696081&amp;dopt=Abstract" target="new">[PMID: 17696081]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952941"></a>Vinnicombe S et al. Full-field digital versus screen-film <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>: comparison within the UK breast screening program and systematic review of published data. Radiology. 2009 May;251(2):347–58. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19401569&amp;dopt=Abstract" target="new">[PMID: 19401569]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178687"></a>Warner E et al. Systematic review: using magnetic resonance 
imaging to screen women at high risk for breast cancer. Ann Intern 
Med. 2008 May 6;148(9):671–9. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18458280&amp;dopt=Abstract" target="new">[PMID: 18458280]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178688"></a>Weaver DL et al. Pathologic findings from the Breast Cancer 
Surveillance Consortium: population-based outcomes in women undergoing 
biopsy after screening <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>. Cancer. 2006 Feb 15;106(4):732–42. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16411214&amp;dopt=Abstract" target="new">[PMID: 
16411214]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178689"></a>Whitman GJ et al. Workup and staging of locally advanced breast cancer. Semin Radiat Oncol. 2009 Oct;19(4):211–21.  
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19732685&amp;dopt=Abstract" target="new">[PMID: 
19732685]</a><br><br class="Spacer10"></td></tr></tbody></table><a name="24229"></a><p class="contentHead5">Clinical Findings 
Associated with  
Early Detection of Breast Cancer</p><a name="8620"></a>
				<p class="contentHead8">Symptoms and Signs</p><a name="8621"></a><p class="contentBody">The presenting complaint in about 70% of patients with 
breast cancer is a lump (usually painless) in the breast. About 
90% of these breast masses are discovered by the patient. 
Less frequent symptoms are breast pain; nipple discharge; erosion, 
retraction, enlargement, or itching of the nipple; and redness, generalized 
hardness, enlargement, or shrinking of the breast. Rarely, an axillary 
mass or swelling of the arm may be the first symptom. Back or bone pain, 
jaundice, or weight loss may be the result of systemic metastases, 
but these symptoms are rarely seen on initial presentation.</p><a name="8622"></a><p class="contentBody">
					The relative frequency of carcinoma in various anatomic sites in the breast is shown in <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8623');">Figure 17–2: illustration</a>.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8623');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_007.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8623');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8623');"><font class="font11">Figure 17–2.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Frequency of breast carcinoma at various anatomic sites. </font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8624"></a><p class="contentBody">Inspection
of the breast is the first step in physical examination and should be
carried out with the patient sitting, arms at her sides and then
overhead. Abnormal variations in breast size and contour, minimal
nipple retraction, and slight edema, redness, or retraction of the skin
can be identified (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8952959');">Figure 17–3</a>).
Asymmetry of the breasts and retraction or dimpling of the skin can
often be accentuated by having the patient raise her arms overhead or
press her hands on her hips to contract the pectoralis muscles.
Axillary and supraclavicular areas should be thoroughly palpated for
enlarged nodes with the patient sitting (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8625');">Figure 17–4: illustration</a>).
Palpation of the breast for masses or other changes should be performed
with the patient both seated and supine with the arm abducted (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8626');">Figure 17–5: illustration</a>). Palpation with a rotary motion of the examiner's fingers as well as a horizontal stripping motion has been recommended.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8952959');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_012.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8952959');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8952959');"><font class="font11">Figure 17–3.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Peau
d'orange sign (resemblance to the skin of an orange due to lymphedema)
in advanced breast cancer. (Courtesy of Richard P. Usatine, MD; used,
with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H,
Tysinger J. The Color Atlas of Family Medicine. McGraw-Hill, 2009.)
</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8625');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_011.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8625');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8625');"><font class="font11">Figure 17–4</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Palpation of axillary region for enlarged lymph nodes. </font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8626');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_002.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8626');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8626');"><font class="font11">Figure 17–5</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Palpation of breasts. Palpation is performed with the patient supine and arm abducted. </font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8627"></a><p class="contentBody">
						Breast cancer usually consists of a nontender, firm or hard mass 
with poorly delineated margins (caused by local infiltration). Very 
small (1–2 mm) erosions of the nipple epithelium may be 
the only manifestation of Paget carcinoma. Watery, serous, or bloody 
discharge from the nipple is an occasional early sign but is more 
often associated with benign disease.</p><a name="8628"></a><p class="contentBody">A small lesion, &lt; 1 cm in diameter, may be difficult 
or impossible for the examiner to feel but may be discovered by 
the patient. She should always be asked to demonstrate the location 
of the mass; if the practitioner fails to confirm the patient's suspicions 
and imaging studies are normal, the examination should be repeated 
in 2–3 months, preferably 1–2 weeks after the 
onset of menses. During the premenstrual 
phase of the cycle, increased innocuous nodularity may suggest neoplasm 
or may obscure an underlying lesion <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23508');">(see x-ray)</a>. If there is any question regarding 
the nature of an abnormality under these circumstances, the patient 
should be asked to return after her period. Ultrasound is often valuable 
and <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> essential when an area is felt by the patient to 
be abnormal but the physician feels no mass. MRI may be considered, 
but the lack of specificity should be discussed by the practitioner 
and the patient. MRI should 
not be used to rule out cancer because MRI has a false-negative 
rate of about 3–5%. Although lower than <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>, this 
false-negative rate cannot permit safe elimination of the possibility 
of cancer. False negatives are more likely seen in infiltrating 
lobular carcinomas and DCIS.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23508');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_010.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23508');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23508');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Scattered fibroglandular tissue. (Courtesy of K Kerlikowske.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8629"></a><p class="contentBody">Metastases tend to involve regional lymph nodes, which may be 
palpable. One or two movable, nontender, not particularly firm axillary 
lymph nodes 5 mm or less in diameter are frequently present and are 
generally of no significance. Firm or hard nodes larger than 1 cm 
are typical of metastases. Axillary nodes that are matted or fixed 
to skin or deep structures indicate advanced disease (at least stage 
III). On the other hand, if the examiner thinks that the axillary 
nodes are involved, that impression will be borne out by histologic 
section in about 85% of cases. The incidence of positive 
axillary nodes increases with the size of the primary tumor. Noninvasive 
cancers (in situ) do not metastasize. Metastases are present in 
about 30% of patients with clinically negative nodes.</p><a name="8630"></a><p class="contentBody">In
most cases, no nodes are palpable in the supraclavicular fossa. Firm or
hard nodes of any size in this location or just beneath the clavicle
are suggestive of metastatic cancer and should be biopsied. Ipsilateral
supraclavicular or infraclavicular nodes containing cancer indicate
that the tumor is in an advanced stage (stage III or IV). Edema of the
ipsilateral arm, commonly caused by metastatic infiltration of regional
lymphatics, is also a sign of advanced cancer.</p><a name="8631"></a>
				<p class="contentHead8">Laboratory Findings</p><a name="8632"></a><p class="contentBody">A
consistently elevated sedimentation rate may be the result of
disseminated cancer. Liver or bone metastases may be associated with
elevation of serum alkaline phosphatase. Hypercalcemia is an occasional
important finding in advanced cancer of the breast. Carcinoembryonic
antigen (CEA) and CA 15-3 or CA 27-29 may be used as markers for
recurrent breast cancer but are not helpful in diagnosing early
lesions. Many scientists are further investigating breast cancer
markers through proteomics and <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1510');">hormone</a> assays. These studies are ongoing and may prove to be helpful in early detection or evaluation 
of prognosis.</p><a name="8633"></a>
				<p class="contentHead8">Imaging for Metastases</p><a name="8634"></a><p class="contentBody">Chest radiographs may show pulmonary metastases. CT scanning 
of the liver and brain is of value only when metastases are suspected 
in these areas. Bone scans utilizing <sup>99m</sup>Tc-labeled phosphates 
or phosphonates are more sensitive than skeletal radiographs in 
detecting metastatic breast cancer. Bone scanning has not proved 
to be of clinical value as a routine preoperative test in the absence 
of symptoms, physical findings, or abnormal alkaline phosphatase 
or calcium levels. The frequency of abnormal findings on bone scan 
parallels the status of the axillary lymph nodes on pathologic examination. PET 
scanning is less useful than a bone scan to identify metastatic 
bone lesions. It is effective in soft tissue or visceral metastases 
in patients with signs or symptoms of metastatic disease. PET scanning 
combined with CT (PET-CT) is an effective screening method for detecting 
soft tissue metastases and is replacing CT scans. </p><a name="8635"></a>
				<p class="contentHead8">Diagnostic Tests</p><a name="8636"></a>
					<p class="contentHead9">Biopsy</p><a name="8637"></a><p class="contentBody">The diagnosis of breast cancer depends ultimately on examination 
of tissue or cells removed by biopsy. Treatment should never be 
undertaken without an unequivocal histologic or cytologic diagnosis 
of cancer. The safest course is biopsy examination of all suspicious 
lesions found on physical examination or <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>, or both. About 
60% of lesions clinically thought to be cancer prove on biopsy 
to be benign, while about 30% of clinically benign lesions 
are found to be malignant. These findings demonstrate the fallibility 
of clinical judgment and the necessity for biopsy. </p><a name="775871"></a><p class="contentBody">All breast masses require a histologic diagnosis with one probable 
exception, a nonsuspicious, presumably fibrocystic mass, in a premenopausal woman. 
Rather, these masses can be observed through one or two menstrual 
cycles. However, if the mass is not cystic and does not completely 
resolve during this time, it must be biopsied. <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8638');">Figures 17–6: illustration</a> and <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8639');">17–7: illustration</a> present algorithms for management 
of breast masses in premenopausal and postmenopausal patients.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8638');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary.gif" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8638');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8638');"><font class="font11">Figure 17–6</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Evaluation of breast masses in premenopausal women.</font><br><br class="Spacer5"><font class="font11">(Adapted, with permission, from Chang S, Haigh 
PI, Giuliano AE.  Breast disease. In: Berek JS, Hacker NF [editors], 
Practical Gynecologic Oncology, 4th edition, LWW, 2004.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8639');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_002.gif" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8639');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8639');"><font class="font11">Figure 17–7</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Evaluation of breast masses in postmenopausal women.</font><br><br class="Spacer5"><font class="font11">(Adapted, with permission, from Chang S, Haigh 
PI, Giuliano AE.  Breast disease. In: Berek JS, Hacker NF [editors], 
Practical Gynecologic Oncology, 4th edition, LWW, 2004.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8640"></a><p class="contentBody">The simplest biopsy method is needle biopsy, either by aspiration 
of tumor cells (FNA cytology) or by obtaining 
a small core of tissue with a hollow needle (core biopsy).</p><a name="8641"></a><p class="contentBody"><b>FNA cytology</b> is a useful technique 
whereby cells are aspirated with a small needle and examined cytologically. 
This technique can be performed easily with virtually no morbidity 
and is much less expensive than excisional or open biopsy. The main disadvantages 
are that it requires a pathologist skilled in the cytologic diagnosis 
of breast cancer and that it is subject to sampling problems, particularly 
because deep lesions may be missed. Furthermore, noninvasive cancers 
usually cannot be distinguished from invasive cancers. The incidence 
of false-positive diagnoses is extremely low, perhaps 1–2%. 
The false-negative rate is as high as 10%. Most experienced 
clinicians would not leave a suspicious dominant mass in the breast 
even when FNA cytology is negative unless the clinical diagnosis, breast 
imaging studies, and cytologic studies were all in agreement, such 
as a fibrocystic lesion or fibroadenoma.</p><a name="8642"></a><p class="contentBody"><b>Large-needle (core needle) biopsy</b> removes 
a core of tissue with a large cutting needle. Hand-held biopsy devices 
make large-core needle biopsy of a palpable mass easy and cost effective 
in the office with local anesthesia. As in the case of any needle biopsy, 
the main problem is sampling error due to improper positioning of 
the needle, giving rise to a false-negative test result. Core biopsy 
has the advantage that tumor markers, such as estrogen receptor (ER), 
<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6847');">progesterone</a> receptor (PR) and HER-2/<i>neu</i> overexpression 
can be performed on cores of tissue.</p><a name="8643"></a><p class="contentBody"><b>Open biopsy</b> under local anesthesia 
as a separate procedure prior to deciding upon definitive treatment 
is the most reliable means of diagnosis. Needle biopsy or aspiration, 
when positive, offers a more rapid approach with less expense and 
morbidity, but when nondiagnostic it must be followed by open biopsy. 
It generally consists of an excisional biopsy, which is done through 
an incision with the intent to remove the entire abnormality, not 
simply a sample. Additional evaluation for metastatic disease and therapeutic 
options can be discussed with the patient after the histologic or 
cytologic diagnosis of cancer has been established. In situ cancers 
are not easily diagnosed cytologically and usually require excisional 
biopsy.</p><a name="8645"></a><p class="contentBody">As an alternative in highly suspicious circumstances, the diagnosis 
may be made on frozen section of tissue obtained by open biopsy 
under general anesthesia. If the frozen section is positive, the 
surgeon can proceed immediately with the definitive operation. This 
one-step method is rarely used today except when a cytologic study 
has suggested cancer but is not diagnostic and there is a high clinical 
suspicion of malignancy in a patient well prepared for the diagnosis 
of cancer and its treatment options. </p><a name="8646"></a><p class="contentBody">In general, the two-step approach—outpatient biopsy 
followed by definitive operation at a later date—is preferred 
in the diagnosis and treatment of breast cancer, because patients 
can be given time to adjust to the diagnosis of cancer, can consider 
alternative forms of therapy, and can seek a second opinion if they 
wish. There is no adverse effect from the short delay of the two-step 
procedure.</p><a name="8647"></a>
					<p class="contentHead9">Ultrasonography</p><a name="8648"></a><p class="contentBody">Ultrasonography is performed primarily to differentiate cystic 
from solid lesions but may show signs suggestive of carcinoma. Ultrasonography 
may show an irregular mass within a cyst in the rare case of intracystic 
carcinoma. If a tumor is palpable and feels like a cyst, an 18-gauge 
needle can be used to aspirate the fluid and make the diagnosis 
of cyst. If a cyst is aspirated and the fluid is nonbloody, it does 
not have to be examined cytologically. If the mass does not recur, 
no further diagnostic test is necessary. Nonpalpable mammographic 
densities that appear benign should be investigated with ultrasound 
to determine whether the lesion is cystic or solid. These may even be 
needle biopsied with ultrasound guidance.</p><a name="8649"></a>
					<p class="contentHead9"><font color="#990000"><b><a name="searchTerm"></a>Mammography</b></font></p><a name="8650"></a><p class="contentBody">When a suspicious abnormality is identified by <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> alone 
and cannot be palpated by the clinician, the lesion should be biopsied 
under mammographic guidance. In the computerized stereotactic guided 
core needle technique, a biopsy needle is inserted into the lesion 
with mammographic guidance, and a core of tissue for histologic 
examination can then be examined. Vacuum assistance increases the 
amount of tissue obtained and improves diagnosis.</p><a name="8651"></a><p class="contentBody"><b>Mammographic localization biopsy</b> is 
performed by obtaining a mammogram in two perpendicular views and 
placing a needle or hook-wire near the abnormality so that the surgeon 
can use the metal needle or wire as a guide during operation to locate 
the lesion. After <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> confirms the position of the needle 
in relation to the lesion, an incision is made and the subcutaneous 
tissue is dissected until the needle is identified. Often, the abnormality 
cannot even be palpated through the incision—as is the 
case with microcalcifications—and thus it is essential 
to obtain a mammogram of the specimen to document that the lesion 
was excised. At that time, a second marker needle can further localize 
the lesion for the pathologist. Stereotactic core needle biopsies 
have proved equivalent to mammographic localization biopsies. Core 
biopsy is preferable to mammographic localization for accessible 
lesions since an operation can be avoided. A metal clip should be 
placed after any image-guided core biopsy to facilitate finding 
the site of the lesion if subsequent treatment is necessary.</p><a name="8652"></a><p class="contentHead9">Other imaging modalities</p><a name="8653"></a><p class="contentBody">Other modalities of breast imaging have been investigated for 
diagnostic purposes. Automated breast ultrasonography is useful 
in distinguishing cystic from solid lesions but should be used only 
as a supplement to physical examination and <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font>. Ductography 
may be useful to define the site of a lesion causing a bloody discharge, 
but since biopsy is almost always indicated, ductography may be 
omitted and the blood-filled nipple system excised. Ductoscopy has 
shown some promise in identifying intraductal lesions, especially 
in the case of pathologic nipple discharge, but in practice, this 
technique is rarely used. MRI is highly sensitive but not specific 
and should not be used for screening except in highly selective 
cases. For example, MRI is useful in differentiating scar from recurrence 
postlumpectomy and may be valuable to screen high-risk women (eg, 
women with <i>BRCA</i> mutations). It may 
also be of value to examine for multicentricity when there is a 
known primary cancer; to examine the contralateral breast in women 
with cancer; to examine the extent of cancer, especially lobular 
carcinomas; or to determine the response to neoadjuvant chemotherapy. 
PET scanning does not appear useful in evaluating the breast itself 
but is valuable to examine regional lymphatics and distant metastases.</p><a name="8654"></a><p class="contentHead9">Cytology</p><a name="8655"></a><p class="contentBody">
						Cytologic examination of nipple discharge or cyst fluid may be 
helpful on rare occasions. As a rule, <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> (or ductography) and 
breast biopsy are required when nipple discharge or cyst fluid is 
bloody or cytologically questionable. Ductal lavage, a technique 
that washes individual duct systems with saline and loosens epithelial 
cells for cytologic evaluation, is being evaluated as a risk assessment 
tool but appears to be of little value.</p><a name="8656"></a>
			<p class="contentHead5">Differential Diagnosis</p><a name="8657"></a><p class="contentBody">The lesions to be considered most often in the differential diagnosis 
of breast cancer are the following, in descending order of frequency: 
fibrocystic condition of the breast, fibroadenoma, intraductal papilloma, 
lipoma, and fat necrosis.</p><a name="8658"></a>
			<p class="contentHead5">Staging</p><a name="8659"></a><p class="contentBody">The American Joint Committee on Cancer and the International 
Union Against Cancer have agreed on a TNM (tumor, regional lymph 
nodes, distant metastases) staging system for breast cancer. Using 
the TNM staging system enhances communication between researchers 
and clinicians. <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8660');">Table 17–2</a> outlines the TNM classification.</p><table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8660');" border="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_table.gif" border="0"></a></td><td class="font11" align="left" valign="middle"><b><a href="javascript:windowReference('Reference','popup.aspx?aID=8660');"><b><font class="font12">Table 17–2. TNM staging for breast cancer.</font></b></a></b></td></tr></tbody></table><a name="8661"></a>
			<p class="contentHead5">Pathologic Types</p><a name="8662"></a><p class="contentBody">Numerous pathologic subtypes of breast cancer can be identified 
histologically (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8663');">Table 17–3</a>).</p><table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8663');" border="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_table.gif" border="0"></a></td><td class="font11" align="left" valign="middle"><b><a href="javascript:windowReference('Reference','popup.aspx?aID=8663');"><b><font class="font12">Table 17–3.&nbsp;Histologic types of breast cancer.</font></b></a></b></td></tr></tbody></table><a name="8664"></a><p class="contentBody">Except for the in situ cancers, the histologic subtypes have 
only a slight bearing on prognosis when outcomes are compared after 
accurate staging. Various histologic parameters, such as invasion 
of blood vessels, tumor differentiation, invasion of breast lymphatics, 
and tumor necrosis have been examined, but other than tumor grade 
these have little prognostic value. Genetic analysis for certain 
high-risk genes in the primary tumor appears to offer prognostic 
and therapeutic information.</p><a name="8665"></a><p class="contentBody">The
noninvasive cancers by definition are confined by the basement membrane
of the ducts and lack the ability to spread. However, in patients whose
biopsies show noninvasive intraductal cancer, associated invasive
ductal cancers metastasize to lymph nodes in about 1–3% of cases.</p><a name="8666"></a><p class="contentHead5">Special Clinical Forms of Breast Cancer</p><a name="8667"></a>
				<p class="contentHead8">Paget Carcinoma</p><a name="8668"></a><p class="contentBody">
					Paget carcinoma is not common (about 1% of 
all breast cancers). It affects the nipple and may or may not be 
associated with a breast mass. The basic lesion is usually a well 
differentiated infiltrating ductal carcinoma or a ductal carcinoma 
in situ (DCIS). The ducts of the nipple epithelium are infiltrated, but 
gross nipple changes are often minimal, and a tumor mass may not 
be palpable.</p><a name="8669"></a><p class="contentBody">
					Because the nipple changes appear innocuous, the diagnosis is 
frequently missed. The first symptom is often itching or burning 
of the nipple, with superficial erosion or ulceration. These are 
often diagnosed and treated as dermatitis or bacterial infection, 
leading to delay or failure in detection. The diagnosis is established 
by biopsy of the area of erosion. When the lesion consists of nipple 
changes only, the incidence of axillary metastases is &lt; 5%, 
and the prognosis is excellent. When a breast mass is also present, 
the incidence of axillary metastases rises, with an associated marked 
decrease in prospects for cure by surgical or other treatment.</p><a name="8670"></a>
				<p class="contentHead8">Inflammatory Carcinoma</p><a name="8671"></a><p class="contentBody">This is the most malignant form of breast cancer and constitutes 
&lt; 3% of all cases. The clinical findings consist 
of a rapidly growing, sometimes painful mass that enlarges the breast. 
The overlying skin becomes erythematous, edematous, and warm. Often 
there is no distinct mass, since the tumor infiltrates the involved 
breast diffusely. 
The inflammatory changes, often mistaken for an infection, are caused 
by carcinomatous invasion of the subdermal lymphatics <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23513');">(see photograph)</a>, with resulting 
edema and hyperemia <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23512');">(see micrograph)</a>. If the practitioner suspects infection but 
the lesion does not respond rapidly (1–2 weeks) to antibiotics, 
biopsy should be performed. The diagnosis 
should be made when the redness involves more than one-third of 
the skin over the breast and biopsy shows infiltrating carcinoma 
with invasion of the subdermal lymphatics. Metastases tend to occur 
early and widely, and for this reason inflammatory carcinoma is 
rarely curable. Radiation, <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1510');">hormone</a> therapy, and chemotherapy are 
the measures most likely to be of value rather than operation. Mastectomy 
is indicated when chemotherapy and radiation have resulted in clinical 
remission with no evidence of distant metastases. In these cases, 
residual disease in the breast may be eradicated.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23513');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23513');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23513');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Acute mastitis, which can look clinically identical to inflammatory carcinoma. (Courtesy of A Giuliano.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23512');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_006.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23512');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23512');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Inflammatory breast carcinoma, showing dermal lymphatic containing carcinoma cells <i>(arrows)</i>. (Reproduced, with permission, from Chandrasoma P, Taylor CR: <i>Concise Pathology</i>, 2nd ed. Originally published by Appleton &amp; Lange. Copyright © 1995 by The McGraw-Hill Companies, Inc.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8672"></a>
			<p class="contentHead5">Breast Cancer Occurring during Pregnancy or Lactation</p><a name="8673"></a><p class="contentBody">Breast cancer complicates approximately one in 3000 pregnancies. 
The diagnosis is frequently delayed, because physiologic changes 
in the breast may obscure the lesion. When the cancer is confined to 
the breast, the 5-year survival rate is about 70%. In 60–70% of 
patients, axillary metastases are already present, conferring a 
5-year survival rate of 30–40%. Pregnancy (or 
lactation) is not a contraindication to operation or treatment, 
and therapy should be based on the stage of the disease as in the nonpregnant 
(or nonlactating) woman. Overall survival rates have improved, since 
cancers are now diagnosed in pregnant women earlier than in the 
past and treatment has improved. Breast-conserving surgery may be 
performed—and radiation and chemotherapy given—even 
during the pregnancy.</p><a name="8674"></a>
			<p class="contentHead5">Bilateral Breast Cancer</p><a name="8675"></a><p class="contentBody">
				Bilateral breast cancer occurs 
in &lt; 5% of cases, but there is as high as a 20–25% incidence 
of later occurrence of cancer in the second breast. Bilaterality 
occurs more often in familial breast cancer, in women under age 50 
years, and when the tumor in the primary breast is lobular. The 
incidence of second breast cancers increases directly with the length 
of time the patient is alive after her first cancer—about 
1–2% per year.</p><a name="8676"></a><p class="contentBody">
				In patients with breast cancer, <font color="#990000"><b><a name="searchTerm"></a>mammography</b></font> should be performed 
before primary treatment and at regular intervals thereafter, to 
search for occult cancer in the opposite breast or conserved ipsilateral breast. 
MRI may be useful in this high-risk group.</p><a name="8677"></a>
			<p class="contentHead5">Noninvasive Cancer</p><a name="8678"></a><p class="contentBody">Noninvasive cancer can occur within the ducts (DCIS) or lobules (lobular carcinoma in situ, LCIS). LCIS, 
although thought to be a premalignant lesion or a risk factor for 
breast cancer, in fact may behave like DCIS. In a 2004 analysis 
of multiple NSABP studies, invasive lobular breast cancer not only 
developed in patients with LCIS but it developed in the same breast 
and indexed location as the original LCIS. Although more research 
needs to be done in this area, the invasive potential of LCIS is 
being reconsidered. The 
subtype pleomorphic LCIS may behave more like DCIS. DCIS tends to be unilateral and most often progresses 
to invasive cancer if untreated. In approximately 40–60% of 
women who have DCIS treated with biopsy alone, invasive cancer develops 
within the same breast. </p><a name="8679"></a><p class="contentBody">
				The treatment of intraductal lesions is controversial. DCIS can 
be treated by wide excision with or without radiation therapy or 
with total mastectomy. Conservative management is advised in patients with 
small lesions amenable to lumpectomy. Although research is defining 
the malignant potential of LCIS, it can be managed with observation. 
Patients unwilling to accept the increased risk of breast cancer 
may be offered surgical excision of the area in question or bilateral 
total mastectomy. Currently, the accepted standard of care offers 
the alternative of chemoprevention, which is effective in preventing 
invasive breast cancer in both LCIS and DCIS that has been completely 
excised. Axillary metastases from in situ cancers should not occur 
unless there is an occult invasive cancer. Sentinel node biopsy 
may be indicated in large DCIS treated with mastectomy.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top">Barnes DM et al. Pregnancy-associated breast cancer: 
a literature review. Surg Clin North Am. 2007 Apr;87(2):417–30.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17498535&amp;dopt=Abstract" target="new">[PMID: 
17498535]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Chia S et al. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008 Feb 10;26(5):786–90. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18258987&amp;dopt=Abstract" target="new">[PMID: 
18258987]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Dalberg K et al. Paget's disease of the nipple in a population based cohort. Breast Cancer Res Treat. 2008 Sep;111(2):313–9. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17952590&amp;dopt=Abstract" target="new">[PMID: 
17952590]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Desmedt
C et al. Strong time dependence of the 76-gene prognostic signature for
node-negative breast cancer patients in the TRANSBIG multicenter
independent validation series. Clin Cancer Res. 2007 Jun
1;13(11):3207–14. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17545524&amp;dopt=Abstract" target="new">[PMID: 
17545524]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Hansen NM et al. Breast cancer: pre- and postoperative imaging 
for staging. Surg Oncol Clin N Am. 2007 Apr;16(2):447–63.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17560522&amp;dopt=Abstract" target="new">[PMID: 
17560522]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952942"></a>Ho BC et al. Lobular neoplasia of the breast: 68 years on. Pathology. 2009 Jan;41(1):28–35. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19089737&amp;dopt=Abstract" target="new">[PMID: 19089737]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Irvine T et al. Biology and treatment of ductal carcinoma in situ. 
Expert Rev Anticancer Ther. 2007 Feb;7(2):135–45.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17288525&amp;dopt=Abstract" target="new">[PMID: 
17288525]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Molckovsky A et al. Breast cancer in pregnancy: a literature review. Breast Cancer Res Treat. 2008 Apr;108(3):333–8. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17530426&amp;dopt=Abstract" target="new">[PMID: 17530426]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Navrozoglou I et al. Breast cancer during pregnancy: a mini-review. Eur J Surg Oncol. 2008 Aug;34(8):837–43. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18343083&amp;dopt=Abstract" target="new">[PMID: 
18343083]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952943"></a>Sakorafas
GH et al. Recent advances and current controversies in the management
of DCIS of the breast. Cancer Treat Rev. 2008 Oct;34(6):483–97. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18490111&amp;dopt=Abstract" target="new">[PMID: 18490111]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Schirrmeister H. Detection of bone metastases in breast cancer by 
positron emission tomography. Radiol Clin North Am. 2007 Jul;45(4):669–76.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17706531&amp;dopt=Abstract" target="new">[PMID: 
17706531]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Theriault R et al. Management of breast cancer in pregnancy. Curr 
Oncol Rep. 2007 Jan;9(1):17–21.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17164043&amp;dopt=Abstract" target="new">[PMID: 
17164043]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178690"></a>Tohno E et al. Ultrasound screening of breast cancer. Breast 
Cancer. 2009;16(1):18–22. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19009372&amp;dopt=Abstract" target="new">[PMID: 19009372]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">West JG et al. Multidisciplinary management of ductal carcinoma 
in situ: a 10-year experience. Am J Surg. 2007 Oct;194(4):532–4.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17826074&amp;dopt=Abstract" target="new">[PMID: 
17826074]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952944"></a>Woodward WA et al. Inflammatory breast cancer. Semin Radiat Oncol. 2009 Oct;19(4):256–65. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19732690&amp;dopt=Abstract" target="new">[PMID: 19732690]</a><br><br class="Spacer10"></td></tr></tbody></table><a name="8680"></a>
			<p class="contentHead3">Biomarkers &amp; Gene Expression Profiling</p><a name="8681"></a><p class="contentBody">It
is critical that the ER, PR and HER-2/neu status of the tumor be
determined, both to gauge a patient’s prognosis and to determine the
best treatment regimen. In addition to ER status and PR status, the
rate at which tumor divides (assessed by an immunohistochemical stain
for Ki-67) and the grade and differentiation of the cells are also
important prognostic factors.</p><a name="8682"></a><p class="contentBody">These
markers may be obtained on core biopsy or surgical specimens. The
presence or absence of ER and PR is a critical element of breast cancer
management. Patients whose primary tumors are receptor-positive have a
more favorable course than those whose tumors are receptor-negative.
While up to 60% of patients with metastatic breast cancer will respond
to hormonal manipulation if their tumors are ER-positive, &lt; 5% of
patients with metastatic, ER-negative tumors will respond. PR status
may be more sensitive than ER status in determining which patients are
likely to respond to hormonal manipulation. Up to 80% of patients with
metastatic PR-positive tumors improve with hormonal manipulation.
Adjuvant endocrine therapy, with or without chemotherapy, in
receptor-positive tumors and adjuvant chemotherapy alone in
receptor-negative tumors improve survival rates even in the absence of
lymph node metastases. </p><a name="8684"></a><p class="contentBody">
				Another key element in determining treatment and prognosis is the amount of the <i>HER-2/neu</i> oncogene present in the cancer. <i>HER-2/neu</i>
overexpression is measured by an immunohistochemical assay that is
scored using a numerical system: 0 and 1+ are not overexpressors, 2+ is
borderline, and 3+ is an overexpressor. In the case of 2+ expression,
fluorescence in situ hybridization (FISH) is recommended to more
accurately assess <i>HER-2/neu</i> amplification. According to the
College of American Pathologists, a FISH score of &lt; 1.8 is negative
for amplification, 1.8–2.2 is indeterminant, and &gt; 2.2 is amplified.
The presence of <i>HER-2/neu</i> amplification and overexpression predicts the response to trastuzumab.</p><a name="8952960"></a><p class="contentBody">While
individually these biomarkers provide insight to appropriate therapy,
when combined they provide a great deal of information regarding risk
of recurrence. Several tests now predict relapse rates for patients
treated with tamoxifen or chemotherapy. Oncotype DX (Genomic Health)
evaluates the expression of 21 genes relating to ER, PR, <i>HER-2/neu,</i>
and proliferation in a tumor specimen and categorizes a patient’s risk
of recurrence as high, intermediate, or low risk. In addition to
providing prognostic information, the test also has predictive value
since studies have shown that patients in the high-risk category are
most likely to respond to chemotherapy. This test is primarily
indicated for ER-positive, node-negative tumors but at least one study
has shown that it may also have value in node-positive tumors.
Mammaprint (Agendia) is another assay that is available for evaluating
prognosis. This 70-gene signature is FDA-approved and may be performed
on fresh frozen tumor tissue taken at the time of a patient’s surgery.
This test classifies patients into good and poor prognostic groups to
predict clinical outcome and may be used on patients with hormone
receptor positive or negative breast cancer.</p><a name="8952961"></a><p class="contentBody">Other markers being evaluated are <i>p53,</i>
nm23, DNA 5c exceeding rate (DNA 5cER), G-actin, urokinase-type
plasminogen activator (u-PA), and its type-1 inhibitor (PAI-1). </p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top"><a name="8952945"></a>Albain
KS et al; for The Breast Cancer Intergroup of North America. Prognostic
and predictive value of the 21-gene recurrence score assay in
postmenopausal women with node-positive, oestrogen-receptor-positive
breast cancer on chemotherapy: a retrospective analysis of a randomised
trial. Lancet Oncol. 2010 Jan;11(1):55–65. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=20005174&amp;dopt=Abstract" target="new">[PMID: 20005174]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178691"></a>Badve S et al. Oestrogen-receptor-positive breast 
cancer: toward bridging histopathological and molecular classifications. 
J Clin Pathol. 2009 Jan;62(1):6–12. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18794199&amp;dopt=Abstract" target="new">[PMID: 18794199]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Ferretti G et al. sHER2<i>/neu</i> role in breast 
cancer: from a prognostic foe to a predictive friend. Curr Opin 
Obstet Gynecol. 2007 Feb;19(1):56–62.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17218853&amp;dopt=Abstract" target="new">[PMID: 
17218853]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Luadido J et al. HER2 testing: a review of detection methodologies 
and their clinical performance. Expert Rev Mol Diagn. 2007 Jan;7(1):53–64.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17187484&amp;dopt=Abstract" target="new">[PMID: 
17187484]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Nicolini A et al. Biomolecular markers of breast cancer. Front Biosci. 
2006 May 1;11:1818–43.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16368559&amp;dopt=Abstract" target="new">[PMID: 
16368559]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178692"></a>Retèl VP et al. Constructive Technology Assessment 
(CTA) as a tool in coverage with evidence development: the case 
of the 70-gene prognosis signature for breast cancer diagnostics. 
Int J Technol Assess Health Care. 2009 Jan;25(1):73–83. 
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19126254&amp;dopt=Abstract" target="new">[PMID: 19126254]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952946"></a>Wolff
AC et al. American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. Arch Pathol Lab Med.
2007;131(1):18–43. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19548375&amp;dopt=Abstract" target="new">[PMID: 19548375]</a><br><br class="Spacer10"></td></tr></tbody></table><a name="8685"></a>
			<p class="contentHead3">Treatment: Curative</p><a name="3175502"></a><p class="contentBody">Clearly, not all breast cancer is systemic at the time of diagnosis. 
For this reason, a pessimistic attitude concerning the management 
of breast cancer is unwarranted. Most patients with early breast 
cancer can be cured.</p><a name="8686"></a><p class="contentBody">Treatment may be curative or palliative. Curative treatment is 
advised for clinical stage I, II, and III disease (see <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8660');">Tables 17–2</a>, <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=778738');">39–3</a>, <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=778763');">39–4</a>). Patients with locally advanced (T3, T4) and 
even inflammatory tumors may be cured with multimodality therapy, 
but in most palliation is all that can be expected. Palliative treatment is 
appropriate for all patients with stage IV disease and for previously 
treated patients in whom distant metastases develop or who have 
unresectable local cancers (see <a href="http://www.accessmedicine.com/content.aspx?aID=8714#8714" target="_parent">Palliative</a> section below).</p><a name="8690"></a><p class="contentHead5">Choice and Timing of Primary Therapy</p><a name="8691"></a><p class="contentBody">The
extent of disease and its biologic aggressiveness are the principal
determinants of the outcome of primary therapy. Clinical and pathologic
staging help in assessing extent of disease (see <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8660');">Table 17–2</a>), but each is to some extent imprecise. Other factors such as tumor grade, hormone receptor assays, and <i>HER-2/neu</i>
oncogene amplification are of prognostic value and are key to
determining systemic therapy, but are not important in determining the
type of local therapy. </p><a name="8692"></a><p class="contentBody">Controversy
has surrounded the choice of primary therapy of stage I, II, and III
breast carcinoma. Currently, the standard of care for stage I, stage
II, and most stage III cancer is surgical resection followed by
adjuvant radiation or systemic therapy, or both, when indicated.
Neoadjuvant therapy is becoming more popular since large tumors may be
shrunk by chemotherapy prior to surgery, making some patients who
require mastectomy candidates for lumpectomy. It is important for
patients to understand all of the surgical options, including
reconstructive options, prior to having surgery. Patients with large
primary tumors, inflammatory cancer, or palpably enlarged lymph nodes
should take the time needed to have staging scans performed to rule out
metastatic disease prior to definitive surgery. In general, adjuvant
systemic therapy is started when the breast has adequately healed,
usually within 4–8 weeks after surgery. While no prospective studies
have defined the appropriate timing of adjuvant chemotherapy, one
retrospective population-based study has suggested that chemotherapy
should be initiated within 12 weeks of surgery to avoid a compromise in
relapse free- and overall survival.</p><a name="3175503"></a><p class="contentHead5">Surgical 
Resection</p><a name="8693"></a>
					<p class="contentHead8">Breast-Conserving Therapy</p><a name="8694"></a><p class="contentBody">Multiple, large, randomized studies including the Milan and NSABP trials 
show that disease-free and overall survival rates are similar for 
patients treated with partial mastectomy plus axillary dissection 
followed by radiation therapy and for those treated by modified radical 
mastectomy (total mastectomy plus axillary dissection). </p><a name="3175504"></a><p class="contentBody">Twenty years of follow-up of the NSABP trial has shown that lumpectomy 
with axillary dissection followed by postoperative radiation therapy 
is as effective as modified radical mastectomy for the management 
of patients with stage I and stage II breast cancer. </p><a name="8697"></a><p class="contentBody">Tumor
size is a major consideration in determining the feasibility of breast
conservation. The lumpectomy trial of the NSABP randomized patients
with tumors as large as 4 cm. To achieve an acceptable cosmetic result,
the patient must have a breast of sufficient size to enable excision of
a 4-cm tumor without considerable deformity. Therefore, large size is
only a relative contraindication. Subareolar tumors, also difficult to
excise without deformity, are not contraindications to breast
conservation. Clinically detectable multifocality is a relative
contraindication to breast-conserving surgery, as is fixation to the
chest wall or skin or involvement of the nipple or overlying skin. The
patient—not the surgeon—should be the judge of what is cosmetically
acceptable.</p><a name="8698"></a><p class="contentBody">Axillary dissection is valuable in preventing axillary recurrences, 
in staging cancer, and in planning therapy. Intraoperative lymphatic 
mapping and sentinel node biopsy identify lymph nodes most likely to 
harbor metastases if present in the axillary nodes (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=3177076');">Figure 17–8</a>). Sentinel node 
biopsy is a reasonable alternative to axillary dissection in selected 
patients with invasive cancer.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=3177076');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_004.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=3177076');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=3177076');"><font class="font11">Figure 17–8.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Sentinel node. (Courtesy of Guilano, AE.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><p class="contentBody">Breast-conserving surgery with radiation is the preferred form 
of treatment for patients with <b>early-stage 
breast cancer</b>. Despite the numerous randomized trials showing 
no survival benefit of mastectomy over breast-conserving partial 
mastectomy and irradiation, breast-conserving surgery still appears underutilized.</p><a name="3175505"></a><p class="contentHead8">Mastectomy</p><a name="8701"></a><p class="contentBody">
Modified radical mastectomy was the standard therapy for most patients
with early-stage breast cancer. This operation removes the entire
breast, overlying skin, nipple, and areolar complex as well as the
underlying pectoralis fascia with the axillary lymph nodes in
continuity <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23515');">(see photograph)</a>.
The major advantage of modified radical mastectomy is that radiation
therapy may not be necessary, although radiation may be used when
multiple lymph nodes involved with cancer. The disadvantage of
mastectomy is the cosmetic and psychological impact associated with
breast loss. Radical mastectomy, which removes the underlying
pectoralis muscle, should be performed rarely, if at all. Axillary node
dissection is not indicated for noninfiltrating cancers because nodal
metastases are rarely present. Skin-sparing mastectomy is currently
gaining favor but is not appropriate for all patients.
Breast-conserving surgery and radiation should be offered whenever
possible, since most patients would prefer to save the breast. Breast
reconstruction, immediate or delayed, should be discussed with patients
who choose or require mastectomy. Patients should have an interview
with a reconstructive plastic surgeon to discuss options prior to
making a decision regarding reconstruction. Time is well spent
preoperatively in educating the patient and family about these matters.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="tableThumbnailLegend" align="left" valign="top" width="90"><table bgcolor="#d1d8de" border="0" cellpadding="2" cellspacing="0" width="100%"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23515');"><img style="border: 1px solid rgb(0, 0, 255);" src="Chapter%2017.%20Breast%20Disorders_archivos/loadBinary_013.jpeg" height="150" width="180"></a></td></tr><tr><td class="font11" align="center" valign="top"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" height="2"><br><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23515');">View Large</a></b></td></tr></tbody></table></td><td width="3"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="3"></td><td class="tableThumbnailLegend" style="border-top: 1px solid rgb(187, 187, 187); border-bottom: 1px solid rgb(187, 187, 187);" align="left" valign="top" width="100%"><table border="0" cellpadding="0" cellspacing="0" height="1" width="100%"><tbody><tr><td align="left"><b><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=23515');"><font class="font11">Fig.</font></a></b></td><td align="right"><b><a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);" border="1" class="font11">Add to 'My Saved Images'</a></b></td></tr></tbody></table><br class="Spacer5">&nbsp;<font class="font11">Modified radical mastectomy defect. (Courtesy of A Giuliano.)</font><br><br class="Spacer5"></td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td></tr></tbody></table></td></tr></tbody></table><br class="Spacer8"><a name="8952962"></a><p class="contentHead5">Radiotherapy</p><a name="775874"></a><p class="contentBody">Radiotherapy
after partial mastectomy consists of 5–7 weeks of five daily fractions
to a total dose of 5000–6000 cGy. Most radiation oncologists use a
boost dose to the cancer location. Several studies are underway
examining the utility and recurrence rates after intraoperative
radiation or dose dense radiation in which the time course of radiation
is shortened. Accelerated partial breast irradiation, in which only the
portion of the breast from which the tumor was resected is irradiated
for 1–2 weeks, appears effective in achieving local control. The
American Society of Breast Surgeons Registry Trial reported that in
1440 patients treated with brachytherapy, the 3-year actuarial rate of
ipsilateral breast cancer recurrence was 2.15% and no unexpected
adverse events were seen. Long-term follow-up will be necessary as will
results from ongoing randomized clinical trials comparing brachytherapy
to standard external beam radiation.</p><a name="8952963"></a><p class="contentBody">Current studies suggest that radiotherapy after mastectomy may improve recurrence rates and survival in patients with tumors <img src="Chapter%2017.%20Breast%20Disorders_archivos/greaterorequal.gif" border="0">
5 cm or positive lymph nodes. Researchers are also examining the
utility of axillary irradiation as an alternative to axillary
dissection in the clinically node-negative patient with sentinel node
micrometastases.</p><a name="8703"></a>
				<p class="contentHead5">Adjuvant Systemic Therapy</p><a name="3175506"></a><p class="contentBody">The goal of systemic therapy, including hormone modulating drugs (endocrine therapy), cytotoxic chemotherapy, and the <i>HER-2/neu</i>-targeted
agent trastuzumab, is to kill cancer cells that have escaped the breast
and axillary lymph nodes as micrometastases before they become
macrometastases (ie, stage IV cancer). Systemic therapy improves
survival and is advocated for most patients with curable breast cancer.
In practice, most medical oncologists are currently using adjuvant
chemotherapy for patients with either node-positive or higher-risk (eg,
hormone receptor-negative or <i>HER-2/neu</i>-positive) node-negative
breast cancer and using endocrine therapy for all hormone
receptor–positive invasive breast cancer unless contraindicated.
Prognostic factors other than nodal status that are used to determine
the patient’s risks are tumor size, ER and PR status, nuclear grade,
histologic type, proliferative rate, oncogene expression (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8712');">Table 17–4</a>),
and patient’s age and menopausal status. In general, systemic
chemotherapy decreases the chance of recurrence by about 30% and
hormonal modulation decreases the risk of recurrence by 40–50% (for
hormone receptor–positive cancer). Systemic therapy is usually given
sequentially, rather than concurrently with radiation. In terms of
sequencing, typically chemotherapy is given before radiation and
endocrine therapy is started after radiation therapy. </p><table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8712');" border="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_table.gif" border="0"></a></td><td class="font11" align="left" valign="middle"><b><a href="javascript:windowReference('Reference','popup.aspx?aID=8712');"><b><font class="font12">Table 17–4.&nbsp;Prognostic 
factors in node-negative breast cancer.</font></b></a></b></td></tr></tbody></table><a name="8952964"></a><p class="contentBody">The
long-term advantage of systemic therapy has been well established. All
patients with invasive hormone receptor–positive tumors should consider
the use of hormone-modulating therapy. Most patients with <i>HER-2/neu</i>-positive
tumors should receive trastuzumab-containing chemotherapy regimens. In
general, adjuvant systemic chemotherapy should not be given to women
who have small node-negative breast cancers with favorable histologic
findings and tumor markers. The ability to predict more accurately
which patients with <i>HER-2/neu</i>-negative, hormone
receptor-positive, lymph node-negative tumors should receive
chemotherapy is improving with the advent of prognostic tools, such as
Oncotype DX and Mammaprint. These tests are now undergoing prospective
evaluation in two clinical trials (TAILORx and MINDACT). </p><a name="776321"></a><p class="contentHead8">Chemotherapy</p><a name="8704"></a><p class="contentBody">The
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
meta-analysis involving over 28,000 women enrolled in 60 trials of
adjuvant polychemotherapy versus no chemotherapy demonstrated a
significant beneficial impact of chemotherapy on clinical outcome in
early breast cancer. This study showed that adjuvant chemotherapy
reduces the risk of recurrence and breast cancer–specific mortality in
all women but also showed that women under the age of 50 derive the
greatest benefit. </p><a name="3178741"></a><p class="contentBody">On the basis of the superiority of <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1187');">anthracycline</a>-containing regimens 
in metastatic breast cancer, both <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6075');">doxorubicin</a> and <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6114');">epirubicin</a> have 
been studied extensively in the adjuvant setting. Studies comparing 
Adriamycin (doxorubicin) and <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=5959');">cyclophosphamide</a> (<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7197');">AC</a>) or epirubicin 
and cyclophosphamide (EC) with cyclophosphamide-<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6555');">methotrexate</a>-<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6215');">5-fluorouracil</a> (CMF) 
have shown that treatments with anthracycline-containing regimens 
are at least as effective, and perhaps more effective, than treatment 
with CMF. The EBCTCG analysis including over 14,000 patients enrolled in trials comparing 
anthracycline-based regimens to CMF, showed a small but statistically 
significant improved disease-free and overall survival with the 
use of anthracycline-based regimens. It should be noted, however, 
that most of these studies included a mixed population of <i>HER-2/neu</i>-positive and <i>HER-2/neu</i>-negative breast 
cancer patients and were performed before the development of <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7087');">trastuzumab</a>. 
Retrospective analyses of a number of these studies suggest 
that anthracyclines may be primarily effective in tumors with <i>HER-2/neu</i> overexpression or 
alteration in the expression of topoisomerase IIa (the target of anthracyclines 
and close to the <i>HER-2/neu </i>gene). 
Given this, for <i>HER-2/neu</i>-negative, 
node-negative breast cancer, four cycles of AC or six cycles of 
CMF are probably equally effective. </p><a name="3178742"></a><p class="contentBody">When
taxanes (T=paclitaxel and docetaxel) emerged in the 1990s, multiple
trials were conducted to evaluate their use in combination with
anthracycline-based regimens. The majority of these trials showed an
improvement in disease-free survival and at least one showed an
improvement in overall survival with the taxane-based regimen. Several
regimens have been reported including AC followed by paclitaxel or
docetaxel (AC-T), TAC (docetaxel concurrent with AC), 5-fluorouracil
(F)EC-docetaxel and FEC-paclitaxel. A meta-analysis of taxane versus
non-taxane anthracycline-based regimen trials showed an improvement in
disease-free and overall survival for the taxane based regimens.
Results from CALGB 9741 showed that compared with a standard dose
regimen, administration of “dose-dense” AC-P chemotherapy (that is, in
an accelerated fashion, in which the frequency of administration is
increased without changing total dose or duration) with granulocyte
colony stimulating factor (G-CSF) support led to improved both
disease-free (82% vs 75% at 4 years) and overall survival (92% vs 90%).
Exploratory subset analysis suggested that patients with hormone
receptor–negative tumors derived the most benefit from the dose-dense
approach. </p><a name="3178743"></a><p class="contentBody">The US
Oncology trial 9735 compared four cycles of AC with four cycles of
Taxotere (docetaxel) and cyclophosphamide (TC). With a median of 7
years follow-up, this study showed a statistically significantly
improved disease-free survival and overall survival in the patients who
received TC. Until this, no trial had compared a non-anthracycline,
taxane-based regimen to an anthracycline-based regimen. </p><a name="3178744"></a><p class="contentBody">An
important ongoing study (US Oncology 06090) is prospectively evaluating
whether anthracyclines add any incremental benefit to a taxane-based
regimen by comparing six cycles of TAC to six cycles of TC in <i>HER-2/neu</i>
negative breast cancer patients. While awaiting the results of this
trial, oncologists are faced with choosing from among the above
treatment regimens for <i>HER-2/neu</i>-negative breast cancer. Given
the benefits described above, taxanes are now used for most patients
receiving chemotherapy for early breast cancer.</p><a name="3178745"></a><p class="contentBody">The
overall duration of adjuvant chemotherapy still remains uncertain.
However, based on the meta-analysis performed in the Oxford Overview
(EBCTCG), the current recommendation is for 3–6 months of the commonly
used regimens. Although it is clear that dose intensity to a specific
threshold is essential, there is little, if any, evidence to support
the long-term survival benefit of high-dose chemotherapy with stem cell
support.</p><a name="3178746"></a><p class="contentBody">Chemotherapy
side effects are now generally well controlled. Nausea and vomiting are
abated with drugs that directly affect the central nervous system, such
as ondansetron and granisetron. Infertility and premature ovarian
failure are common side effects of chemotherapy, especially in women
over the age of 40, and should be discussed with patients prior to
starting treatment. The risk of life-threatening neutropenia associated
with chemotherapy can be reduced by use of growth factors such as
pegfilgrastim and filgrastim (G-CSF), which stimulate proliferation and
differentiation of hematopoietic cells. Long-term toxicities from
chemotherapy, including cardiomyopathy (anthracyclines) and
leukemia/myelodysplasia (anthracyclines and alkylating agents), remain
a small but significant risk. </p><a name="776323"></a>
					<p class="contentHead8">Targeted 
Therapy</p><a name="3175507"></a><p class="contentHead9">HER-2/<i>neu</i> 
overexpression</p><a name="776324"></a><p class="contentBody">Twenty percent of breast cancers have overexpression or amplification of the <i>HER-2/neu</i> oncogene. The poor prognosis associated with <i>HER-2/neu</i> overexpression has been drastically improved with the development of HER-2/neu-targeted therapy. <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7087');">Trastuzumab</a> (Herceptin [H]), a <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6611');">monoclonal antibody</a> 
that binds to <i>HER-2/neu</i> receptors, 
has proved effective in combination with chemotherapy in patients 
with <i>HER-2/neu</i> overexpressing 
metastatic and early breast cancer. In the adjuvant setting, the first 
and most commonly studied chemotherapy backbone used with trastuzumab 
is <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7197');">AC</a>-T. More recently, the BCIRG006 study showed equivalent efficacy 
for AC-TH versus TCH (<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6060');">docetaxel</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=5822');">carboplatin</a>, trastuzumab). Both AC-TH 
and TCH are now FDA-approved for early, <i>HER-2/neu</i>-positive 
breast cancer. In these regimens, trastuzumab is given with chemotherapy and 
then continues beyond the course of chemotherapy to complete a full 
year. Other studies have evaluated use of a shorter course of trastuzumab 
(FinHer trial) and use of trastuzumab sequentially 
(not concurrently) with chemotherapy (Herceptin Adjuvant or HERA trial). 
Although both of these studies showed benefits of adding trastuzumab 
to chemotherapy, the current standard remains 1 full year of trastuzumab 
for adjuvant therapy. Several questions relating to the treatment of early <i>HER-2/neu</i>-positive
breast cancer remain unanswered. One such question is whether to treat
small (&lt; 1 cm), node-negative tumors with trastuzumab plus
chemotherapy. Studies have shown that even small (stage T1a,b) <i>HER-2/neu</i>-positive tumors have a worse prognosis compared with same-sized <i>HER-2/neu</i>-negative
tumors. Prospective studies are ongoing to address whether
trastuzumab-based chemotherapy regimens are appropriate for these
patients.</p><a name="3178747"></a><p class="contentBody">Cardiomyopathy
develops in a small but significant percent (1–4%) of patients who
receive trastuzumab-based regimens. For this reason, anthracyclines and
trastuzumab are usually not given concurrently and cardiac function is
monitored periodically throughout therapy. </p><a name="3175510"></a><p class="contentHead9">Endocrine 
therapy</p><a name="8711"></a><p class="contentBody">Adjuvant
hormone modulation therapy is highly effective in decreasing recurrence
and mortality by 25% in women with hormone receptor-positive tumors
regardless of menopausal status. The traditional regimen has been 5
years of the estrogen-receptor antagonist/agonist tamoxifen, and this
remains the standard for premenopausal women. Ovarian ablation in
premenopausal patients with ER-positive tumors may produce a benefit
similar to that of adjuvant systemic chemotherapy. Whether the use of
ovarian ablation plus tamoxifen (or ovarian ablation plus an aromatase
inhibitor [AI]) is more effective than either measure alone is unclear
and is currently being addressed in ongoing clinical trials
(Suppression of Ovarian Function Trial [SOFT] and Tamoxifen and
Exemestane Trial [TEXT]). AIs, including anastrozole, letrozole, and
exemestane, reduce estrogen production and are also effective in the
adjuvant setting for postmenopausal women. Approximately seven large
randomized trials enrolling more than 24,000 patients have compared the
use of AIs with tamoxifen or placebo as adjuvant therapy. All of these
studies have shown small but statistically significant improvements in
disease-free survival (absolute benefits of 2–6%) with the use of AIs.
In addition, AIs have been shown to reduce the risk of contralateral
breast cancers and to have fewer associated side effects (such as
endometrial cancers and thromboembolic events) than tamoxifen. However,
they are associated with accelerated bone loss and an increased risk of
fractures. The American Society of Clinical Oncology and National
Comprehensive Cancer Network have recommended that postmenopausal women
with hormone receptor–positive breast cancer be offered an AI either
initially or after tamoxifen therapy. <i>HER-2/neu</i> status should not affect the use or choice of hormone therapy. </p><a name="8952965"></a><p class="contentHead8">Bisphosphonates</p><a name="8952966"></a><p class="contentBody">Two
randomized studies (ZO-FAST and ABCSG12) have evaluated the use of an
adjuvant intravenous bisphosphonate (zoledronic acid) in addition to
standard local and systemic therapy. The results showed a 35–40%
relative reduction in the risk of cancer recurrence for hormone
receptor-positive non-metastatic breast cancer; these intriguing
results have led to the development of several ongoing randomized
clinical trials evaluating the use of bone-stabilizing agents for early
breast cancer.</p><a name="8952967"></a><p class="contentBody">Zoledronic
acid is FDA-approved for metastatic cancer involving the bones (given
monthly) and for treatment of osteoporosis (given yearly). In the
ABCSG12 study, zoledronic acid was given every 6 months for 3 years.
Side effects associated with this treatment include bone pain, fever,
osteonecrosis of the jaw (rare), and renal failure. </p><a name="8952968"></a><p class="contentHead8">Adjuvant therapy in older women</p><a name="8952969"></a><p class="contentBody">Data
relating to the optimal use of adjuvant systemic treatment for women
over the age of 65 is limited. Results from the EBCTCG overview
indicates that while adjuvant chemotherapy yields a smaller benefit for
older women compared with younger women, it still improves clinical
outcomes. Moreover, individual studies do show that older women with
higher risk disease derive benefits from chemotherapy. One study
compared the use of oral chemotherapy (capecitabine) to standard
chemotherapy in older women and concluded that standard chemotherapy is
preferred. Another study (USO TC vs AC) showed that women over the age
of 65 derive similar benefits from the taxane-based regimen as women
who are younger. The benefits of endocrine therapy for hormone
receptor-positive disease appears to be independent of age. In general,
decisions relating to the use of systemic therapy should take into
account a patient’s comorbidities and physiological age, more so than
chronologic age.</p><a name="776325"></a><p class="contentHead5">Neoadjuvant 
Therapy</p><a name="776326"></a><p class="contentBody">The
use of chemotherapy or endocrine therapy prior to resection of the
primary tumor (neoadjuvant) is gaining popularity. This enables the
assessment of in vivo chemosensitivity. Patients with hormone
receptor-negative breast cancer are more likely to have a pathologic
complete response to neoadjuvant chemotherapy than those with hormone
receptor-positive breast cancer. A complete pathologic response at the
time of surgery is associated with improvement in survival. Neoadjuvant
chemotherapy also increases the chance of breast conservation by
shrinking the primary tumor in women who would otherwise need
mastectomy for local control. Survival after neoadjuvant chemotherapy
is similar to that seen with postoperative adjuvant chemotherapy.
Neoadjuvant AI therapy has been evaluated in a phase II study involving
115 postmenopausal patients with hormone receptor-positive breast
cancer. The overall response rate was 62% in this study, and 38% of
patients initially ineligible for breast conservation were able to have
lumpectomy. There is considerable concern as to the timing of sentinel
lymph node biopsy (SLNB), since the chemotherapy may affect any cancer
present in the lymph nodes. Several studies have shown that sentinel
node biopsy can be done after neoadjuvant therapy. However, a large
multicenter study, NSABP B-27, demonstrated a false-negative rate of
10.7%, well above the false-negative rate outside the neoadjuvant
setting (&lt; 1–5%). Many physicians recommend performing SLNB before
administering the chemotherapy in order to avoid a false-negative
result and to aid in planning subsequent radiation therapy. If a
complete dissection is necessary, this can be performed at the time of
the definitive breast surgery. </p><a name="3178749"></a><p class="contentBody">Important questions remaining to be answered are the timing and 
duration of adjuvant and neoadjuvant chemotherapy, which chemotherapeutic 
agents should be applied for which subgroups of patients, the use 
of combinations of hormonal therapy and chemotherapy as well as 
possibly targeted therapy, and the value of prognostic factors other 
than <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1510');">hormone</a> receptors in predicting response to therapy.</p><a name="8714"></a>
			<p class="contentHead3">Treatment: Palliative</p><a name="8716"></a>
				<a name="8952970"></a><p class="contentBody">Only
10% of patients have de novo metastatic breast cancer at the time of
diagnosis. However, in most patients who have a breast cancer
recurrence after initial local and adjuvant therapy, the recurrence
presents as metastatic rather than local (in breast) disease. Breast
cancer most commonly metastasizes to the liver, lungs and bone, causing
symptoms such as bone pain, fatigue, change in appetite, abdominal
pain, or respiratory symptoms. Triple negative (ER-, PR-, <i>HER-2/neu</i>-negative) and <i>HER-2/neu</i>-positive tumors have a higher rate of brain metastases than hormone-receptor positive, <i>HER-2/neu</i>-negative tumors. Headaches, imbalance, vision changes, vertigo, and other neurologic symptoms may be signs of brain metastases.</p><p class="contentHead5">Radiotherapy and Bisphosphonates</p><a name="8717"></a><p class="contentBody">Palliative
radiotherapy may be advised for primary treatment of locally advanced
cancers with distant metastases to control ulceration, pain, and other
manifestations in the breast and regional nodes. Irradiation of the
breast and chest wall and the axillary, internal mammary, and
supraclavicular nodes should be undertaken in an attempt to cure
locally advanced and inoperable lesions when there is no evidence of
distant metastases. A small number of patients in this group are cured
in spite of extensive breast and regional node involvement. </p><a name="8718"></a><p class="contentBody">Palliative irradiation is of value also in the treatment of certain 
bone or soft-tissue metastases to control pain or avoid fracture. 
Radiotherapy is especially useful in the treatment of isolated bony 
metastases, chest wall recurrences, brain metastases, and acute 
spinal cord compression.</p><a name="8952971"></a><p class="contentBody">In
addition to radiotherapy, bisphosphonate therapy has shown excellent
results in delaying and reducing skeletal events in women with bony
metastases. Bisphosphonates are routinely given with endocrine therapy
to patients with bone metastases. </p><a name="8952972"></a><p class="contentBody">Caution
should be exercised when combining radiation therapy with chemotherapy
because toxicity of either or both may be augmented by the concurrent
administration. In general, only one type of therapy should be given at
a time unless it is necessary to irradiate a destructive lesion of
weight-bearing bone while the patient is receiving another regimen. The
regimen should be changed only if the disease is clearly progressing.
This is especially difficult to determine for patients with destructive
bone metastases, since changes in the status of these lesions are
difficult to determine radiographically. </p><a name="8719"></a>
				<p class="contentHead5">Targeted Therapy</p><a name="8952973"></a><p class="contentHead8">Endocrine therapy for metastatic disease</p><a name="8720"></a><p class="contentBody">Targeted therapy refers to agents that are directed specifically 
against a protein or molecule expressed uniquely on tumor cells or 
in the tumor microenvironment. The first targeted therapy was the 
use of antiestrogen therapy in <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1510');">hormone</a> receptor–positive 
breast cancer. The administration of hormones (eg, estrogens, androgens, 
progestins; see <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8721');">Table 17–5</a>); 
ablation 
of the ovaries, adrenals, or pituitary; administration of drugs 
that block hormone receptors (eg, antiestrogens such as <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">tamoxifen</a>) 
or drugs that block the synthesis of hormones (eg, AIs) have all 
been shown to be effective in hormone receptor–positive 
metastatic breast cancer. Palliative treatment of metastatic cancer 
should be based on the ER status of the primary tumor or the metastases. 
Because only 5–10% of women with ER-negative tumors 
respond, they should not receive endocrine therapy except in unusual 
circumstances, eg, in an older patient who cannot tolerate chemotherapy. 
The rate of response is nearly equal in premenopausal and postmenopausal women 
with ER-positive tumors. A favorable response to hormonal manipulation occurs 
in about one-third of patients with metastatic breast cancer. Of 
those whose tumors contain ER, the response is about 60% and 
perhaps as high as 80% for patients whose tumors contain 
PR as well. The choice of endocrine therapy depends on the menopausal 
status of the patient. Women within 1 year of their last menstrual period 
are arbitrarily considered to be premenopausal and should receive 
tamoxifen therapy or ovarian ablation, whereas women whose menses 
ceased more than a year before are postmenopausal and may receive 
an <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=35591');">AI</a>. Women with ER-positive tumors who do not respond to endocrine therapy 
or experience progression should be given a different form of hormonal 
manipulation. The initial endocrine treatment used is referred to 
as primary hormonal manipulation; subsequent endocrine treatment 
is called secondary or tertiary hormonal manipulation.</p><table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8721');" border="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_table.gif" border="0"></a></td><td class="font11" align="left" valign="middle"><b><a href="javascript:windowReference('Reference','popup.aspx?aID=8721');"><b><font class="font12">Table 17–5.&nbsp;Agents commonly 
used for hormonal management of metastatic breast cancer.</font></b></a></b></td></tr></tbody></table><a name="3178750"></a><p class="contentBody">Because the quality of life during endocrine manipulation is 
usually superior to that during cytotoxic chemotherapy, it is best 
to try endocrine manipulation whenever possible. However, when receptor 
status is unknown, disease is progressing rapidly or involves visceral 
organs, chemotherapy should be used as first-line treatment.</p><a name="8724"></a><p class="contentHead9">The Premenopausal Patient</p><a name="8725"></a><p class="contentHead10">Primary hormonal therapy</p><a name="8726"></a><p class="contentBody">
							The potent <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1671');">SERM</a>&nbsp;<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">tamoxifen</a> is by far the most common and preferred 
method of hormonal manipulation in the premenopausal patient, in 
large part because it can be given with less morbidity and fewer 
side effects than cytotoxic chemotherapy. Tamoxifen is given orally 
in a dose of 20 mg daily. The average remission associated with 
tamoxifen lasts about 12 months.</p><a name="8727"></a><p class="contentBody">
							There is no significant difference in survival or response between 
<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7009');">tamoxifen</a> therapy and bilateral oophorectomy. Bilateral oophorectomy 
is less desirable than tamoxifen in premenopausal women because tamoxifen 
is so well tolerated. However, oophorectomy can be achieved rapidly 
and safely either by surgery, by irradiation of the ovaries if the 
patient is a poor surgical candidate, or by chemical ovarian ablation using 
a <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1497');">gonadotropin</a>-releasing <a href="javascript:windowReference('drugInfo','drugClassification.aspx?catid=1510');">hormone</a> (<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6278');">GnRH</a>) analog. Oophorectomy presumably works 
by eliminating estrogens, progestins, and androgens, which stimulate 
growth of the tumor. AIs should not be used in a patient with functioning 
ovaries since they do not block ovarian production of estrogen.</p><a name="8728"></a><p class="contentHead10">Secondary or tertiary hormonal therapy</p><a name="8729"></a><p class="contentBody">Patients
who do not respond to tamoxifen or ovarian ablation may be treated with
chemotherapy or may try a second endocrine regimen, such as GnRH analog
plus AI. Whether to opt for chemotherapy or another endocrine measure
depends largely on the sites of metastatic disease (visceral being more
serious than bone-only, thus warranting the use of chemotherapy), the
disease burden, the rate of growth of disease and patient preference.
Patients who take chemotherapy and then later have progressive disease
may subsequently respond to another form of endocrine treatment (<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8721');">Table 17–5</a>). The optimal choice for secondary endocrine manipulation has not been clearly defined for the premenopausal patient.</p><a name="8730"></a><p class="contentBody">Patients
who improve after oophorectomy but subsequently relapse should receive
tamoxifen or an AI; if one fails, the other may be tried but is not
likely to succeed. Megestrol acetate, a progesterone agent, may also be
considered. Adrenalectomy or hypophysectomy, procedures rarely done
today, induced regression in 30–50% of patients who previously
responded to oophorectomy. Pharmacologic hormonal manipulation has
replaced these invasive procedures. </p><a name="8731"></a><p class="contentHead9">The Postmenopausal Patient</p><a name="8732"></a><p class="contentHead10">Primary hormonal therapy</p><a name="8733"></a><p class="contentBody">
For postmenopausal women with metastatic breast cancer amenable to
endocrine manipulation, tamoxifen or an AI is the initial therapy of
choice. The side effect profile of AIs differs from tamoxifen and may
be more effective. The main side effects of tamoxifen are nausea, skin
rash, and hot flushes. Rarely, tamoxifen induces hypercalcemia in
patients with bony metastases. Tamoxifen also increases the risk of
venous thromboembolic events and uterine hyperplasia and cancer. The
main side effects of AIs include hot flushes, vaginal dryness, and
joint stiffness; however, osteoporosis and bone fractures are
significantly higher than tamoxifen.</p><a name="8734"></a><p class="contentHead10">Secondary or tertiary hormonal therapy</p><a name="8735"></a><p class="contentBody">
AIs are also used for the treatment of advanced breast cancer in
postmenopausal women after tamoxifen treatment. In the event that the
patient responds to AI but then has progression of disease, an
antiestrogen, fulvestrant, has shown efficacy with about 20–30% of
women benefiting from use. Postmenopausal patients who do not respond
to SERM or AI should be given cytotoxic drugs. Postmenopausal women who
respond initially to a SERM or AI but later manifest progressive
disease may be crossed over to another hormonal therapy. </p><a name="8952974"></a><p class="contentBody">If
they do not respond, they should receive cytotoxic drugs. Androgens
(such as testosterone) have many toxicities and should be used
infrequently. As in premenopausal patients, neither hypophysectomy nor
adrenalectomy should be performed. High-dose estrogen therapy has also
paradoxically been shown to induce responses in advanced breast cancer.
A study that evaluated the use of low-dose (6 mg) versus high-dose (30
mg) estradiol daily orally for postmenopausal women with metastatic
AI-resistant breast cancer showed that the two doses yielded similar
clinical benefit rates (29% and 28%, respectively) and, as expected,
the higher dose was associated with more adverse events than the low
dose. Interestingly, seven patients who progressed after an initial
response to estradiol were re-treated with an AI and, of these, two
patients had a partial response and one had stable disease, indicating
resensitization to the AI.</p><a name="8952975"></a><p class="contentHead8"><i>HER-2/neu</i> targeted agents</p><a name="8952976"></a><p class="contentBody">For patients with <i>HER-2/neu</i> overexpressing or amplified tumors, trastuzumab plus chemotherapy has been shown to increase survival. <b>Lapatinib</b> is a newer oral targeted drug that works by inhibiting the intracellular tyrosine kinases of the endothelial growth factor and <i>HER-2/neu</i> receptors. This drug is FDA-approved for the treatment of trastuzumab-resistant <i>HER-2/neu</i>-positive
metastatic breast cancer in combination with capecitabine, thus, a
completely oral regimen. The combination of trastuzumab plus lapatinib
has been shown to be more effective than lapatinib alone for
trastuzumab-resistant metastatic breast cancer. Moreover, several
trials have now shown a significant clinical benefit for continuing <i>HER-2/neu</i>-targeted agents beyond progression. Multiple drugs targeting the <i>HER-2/neu</i>
pathway are in development, with promising phase I and II clinical
trial results reported for many. A few of these therapeutics in
development include T-DM1, neratinib, pertuzumab, everolimus, and a <i>HER-2/neu</i>-targeted vaccine.</p><a name="8952977"></a><p class="contentHead8">Targeting angiogenesis</p><a name="8952978"></a><p class="contentBody"><b>Bevacizumab</b>
is a monoclonal antibody directed against vascular endothelial growth
factor (VEGF). This growth factor stimulates endothelial proliferation
and neoangiogenesis in cancer. A phase III randomized trial (E2100) in
women with metastatic breast cancer showed increased response rate and
progression-free survival rate with the combination of bevacizumab and
paclitaxel as first-line treatment compared with paclitaxel alone;
however, there was no significant overall survival benefit. This led to
the FDA approval of bevacizumab in early 2008. Since that time, two
additional prospective randomized clinical trials (AVADO and RIBBON-1)
have reported the addition of bevacizumab to standard chemotherapy
improves disease-free survival and objective response rates compared
with single-agent chemotherapy alone. A benefit in overall survival has
not been demonstrated. The RIBBON-2 study is the first randomized study
to show a benefit (in terms of response rate and progression-free
survival) with the use of bevacizumab plus chemotherapy as <i>second</i>-line
therapy for metastatic breast cancer. While these initial results are
promising, studies are now underway to define which patients and tumor
types are most likely to benefit from antiangiogenic agents.</p><a name="8952979"></a><p class="contentHead8">Targeting “triple-negative” breast cancer</p><a name="8952980"></a><p class="contentBody">Until very recently, breast cancers lacking expression of the hormone receptors, ER and PR, and <i>HER-2/neu</i>
have only been amenable to therapy with cytotoxic chemotherapy. This
type of “triple-negative” breast cancer, while heterogeneous, generally
behaves aggressively and is associated with a poor prognosis. Newer
classes of targeted agents are being evaluated specifically for
triple-negative breast cancer. Some triple-negative breast cancers may
be characterized by an inability to repair double-strand DNA breaks
(due to mutation or epigenetic silencing of the <i>BRCA</i> gene). <b>Poly-ADP ribose-polymerase inhibitors (PARP-i)</b> are a new class of agents that prevent the repair of single strand DNA breaks and are showing promise in <i>BRCA</i>-mutated
and triple-negative breast cancer. One relatively small randomized
clinical trial evaluating gemcitabine plus carboplatin with or without
a PARP-I (BSI-201) for triple-negative metastatic breast cancer showed
improved clinical outcomes, including improved overall survival for
PARP-i-treated patients. Research in this area is rapidly expanding
with multiple clinical trials ongoing. </p><a name="8736"></a>
				<p class="contentHead5">Palliative Chemotherapy</p><a name="8737"></a><p class="contentBody">
					Cytotoxic drugs should be considered for the treatment of metastatic 
breast cancer (1) if visceral metastases are present (especially brain, 
liver, or lymphangitic pulmonary), (2) if hormonal treatment is 
unsuccessful or the disease has progressed after an initial response 
to hormonal manipulation, or (3) if the tumor is ER-negative. Prior 
adjuvant chemotherapy does not seem to alter response rates in patients 
who relapse. A number of chemotherapy drugs (including <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=7154');">vinorelbine</a>, 
<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6712');">paclitaxel</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6060');">docetaxel</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6252');">gemcitabine</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=336410');">ixabepilone</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=5822');">carboplatin</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=5907');">cisplatin</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=5804');">capecitabine</a>, 
<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6713');">albumin-bound paclitaxel</a>, and <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6076');">liposomal doxorubicin</a>) may be used 
as single agents with first-line objective response rates ranging 
from 30% to 50%.</p><a name="8738"></a><p class="contentBody">
					Combination chemotherapy yields statistically significantly higher 
response rates and progression-free survival rates, but has not been 
conclusively shown to improve overall survival rates compared with 
sequential single-agent therapy. Combinations that have been tested 
in phase III studies and have proven efficacy compared with single-agent therapy 
include <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=5804');">capecitabine</a>/<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6060');">docetaxel</a>, <a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6252');">gemcitabine</a>/<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=6712');">paclitaxel</a>, and capecitabine/<a href="javascript:windowReference('drugInfo','drugContentPopup.aspx?mid=336410');">ixabepilone</a> (see 
<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8951523');">Tables 39–10</a> and <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8951525');">39–11</a>). Various other combinations of drugs have been tested in phase II 
studies, and a number of clinical trials are ongoing to identify effective 
combinations. For patients whose tumors have progressed after several 
lines of therapy and who are considering additional therapy, clinical 
trial participation with experimental drugs in phase I, II, or III testing 
should be encouraged.</p><a name="8739"></a><p class="contentBody">
					In the past, high-dose chemotherapy and autologous bone marrow 
or stem cell transplantation aroused widespread interest for the 
treatment of metastatic breast cancer. However, multiple clinical 
trials failed to show any improvement in survival with high-dose 
chemotherapy with stem cell transplant over conventional chemotherapy and 
the procedure is now rarely, if ever, performed for stage IV breast 
cancer.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top"><a name="3178693"></a>Albain KS et al. Gemcitabine plus paclitaxel versus 
paclitaxel monotherapy in patients with metastatic breast cancer 
and prior anthracycline treatment. J Clin Oncol. 2008 Aug 20;26(24):3950–7. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18711184&amp;dopt=Abstract" target="new">[PMID: 18711184]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178694"></a>American College of Radiology. Practice guideline for the breast 
conservation therapy in the management of invasive breast carcinoma. 
J Am Coll Surg. 2007 Aug;205(2):362–376. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17660085&amp;dopt=Abstract" target="new">[PMID: 
17660085]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178695"></a>Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group; 
Forbes JF et al. Effect of anastrozole and tamoxifen as adjuvant 
treatment for early-stage breast cancer: 100-month analysis of the 
ATAC trial. Lancet Oncol. 2008 Jan;9(1):45–53. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18083636&amp;dopt=Abstract" target="new">[PMID: 
18083636]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178696"></a>Bhatnagar AS. Review of the development of letrozole and its 
use in advanced breast cancer and in the neoadjuvant setting. Breast. 
2006 Feb;15(Suppl 1):S3–13. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16500235&amp;dopt=Abstract" target="new">[PMID: 16500235]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178697"></a>Carlson RW et al; National Comprehensive Cancer Network. NCCN 
Task Force Report: adjuvant therapy for breast cancer. J Natl Compr 
Canc Netw. 2006 Mar;4(Suppl 1):S1–26. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16507275&amp;dopt=Abstract" target="new">[PMID: 16507275]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178698"></a>Chu QD et al. Adjuvant therapy for patients who have node-positive 
breast cancer. Adv Surg. 2006;40:77–98. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17163096&amp;dopt=Abstract" target="new">[PMID: 
17163096]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178700"></a>Coates AS et al. Five years of letrozole compared with tamoxifen 
as initial adjuvant therapy for postmenopausal women with endocrine-responsive 
early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 
Feb 10;25(5):486–92. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17200148&amp;dopt=Abstract" target="new">[PMID: 17200148]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178701"></a>Coombes RC et al; Intergroup Exemestane Study. Survival and 
safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment: 
a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559–70. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17307102&amp;dopt=Abstract" target="new">[PMID: 
17307102]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952947"></a>De
Laurentiis M et al. Taxane-based combinations as adjuvant chemotherapy
of early breast cancer: a meta-analysis of randomized trials. J Clin
Oncol. 2008 Jan 1:26(1):44–53. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18165639&amp;dopt=Abstract" target="new">[PMID: 18165639]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178702"></a>Dienstmann R et al. Evidence-based neoadjuvant endocrine therapy 
for breast cancer. Clin Breast Cancer. 2006 Oct;7(4):315–20. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17092398&amp;dopt=Abstract" target="new">[PMID: 
17092398]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178703"></a>Ellis
MJ et al. Lower-dose vs high-dose oral estradiol therapy of hormone
receptor-positive, aromatase inhibitor-resistant advanced breast
cancer: a phase 2 randomized study. JAMA. 2009 Aug 19;302(7):774–80.
&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19690310&amp;dopt=Abstract" target="new">[PMID: 19690310]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178705"></a>Fitzal F et al. Breast conservation: evolution of surgical strategies. 
Breast J. 2006 Sep–Oct;12(5 Suppl 2):S165–73. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16958997&amp;dopt=Abstract" target="new">[PMID: 16958997]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178706"></a>Gennari A et al. <i>HER2</i> status and 
efficacy of adjuvant anthracyclines in early breast cancer: a pooled 
analysis of randomized trials. J Natl Cancer Inst. 2008 Jan 2;100(1):14–20. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18159072&amp;dopt=Abstract" target="new">[PMID: 18159072]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178707"></a>Gnant
M et al; ABCSG-12 Trial Investigators. Endocrine therapy plus
zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009 Feb
12;360(7):679–91. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19213681&amp;dopt=Abstract" target="new">[PMID: 19213681]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178708"></a>Gonzalez-Angulo
AM et al. High risk of recurrence for patients with breast cancer who
have human epidermal growth factor receptor 2-positive, node-negative
tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 1;27(34):5700–6. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19884543&amp;dopt=Abstract" target="new">[PMID: 
19884543]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178709"></a>Hurvitz SA et al. What’s positive about triple negative breast cancer? Future Oncol. 2009 Sep;5(7):1015–25.  
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19792970&amp;dopt=Abstract" target="new">[PMID: 19792970]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178710"></a>Ingle JN et al. Fulvestrant in women with advanced breast cancer 
after progression on prior aromatase inhibitor therapy: North Central 
Cancer Treatment Group Trial N0032. J Clin Oncol. 2006 Mar 1;24(7):1052–6. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16505423&amp;dopt=Abstract" target="new">[PMID: 
16505423]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952948"></a>Iwata H. Neo(adjuvant) trastuzumab treatment: current perspectives. Breast Cancer. 2009;16(4):288–94. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19609648&amp;dopt=Abstract" target="new">[PMID: 19609648]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178711"></a>Joensuu
H et al. Fluorouracil, epirubicin, and cyclophosphamide with either
docetaxel or vinorelbine, with or without trastuzumab, as adjuvant
treatments of breast cancer: final results of the FinHer Trial. J Clin
Oncol. 2009 Dec 1;27(34):5685–92. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19884557&amp;dopt=Abstract" target="new">[PMID: 
19884557]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178712"></a>Jones
SE et al. Docetaxel with cyclophosphamide is associated with an overall
survival benefit compared with doxorubicin and cyclophosphamide: 7-year
follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar
10;27(8):1177–83. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19204201&amp;dopt=Abstract" target="new">[PMID: 
19204201]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178714"></a>Kim T et al. Lymphatic mapping and sentinel lymph node biopsy 
in early-stage breast carcinoma: a metaanalysis. Cancer. 2006 Jan 
1;106(1):4–16. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16329134&amp;dopt=Abstract" target="new">[PMID: 16329134]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178715"></a>Lee MC et al. Management of patients with locally advanced breast 
cancer. Surg Clin North Am. 2007 Apr;87(2):379–98. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17498533&amp;dopt=Abstract" target="new">[PMID: 
17498533]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178716"></a>Leonard C et al. Prospective trial of accelerated partial breast 
intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007 
Apr 1;67(5):1291–8. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17234359&amp;dopt=Abstract" target="new">[PMID: 17234359]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178717"></a>Lohrisch
C et al. Impact on survival of time from definitive surgery to
initiation of adjuvant chemotherapy for early-stage breast cancer. J
Clin Oncol. 2006 Oct 20;24(30):4888–94. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17015884&amp;dopt=Abstract" target="new">[PMID: 17015884]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178718"></a>Mieog JS et al. Preoperative chemotherapy for women with operable 
breast cancer. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17443564&amp;dopt=Abstract" target="new">[PMID: 
17443564]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178719"></a>Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel 
alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27;357(26):2666–76. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18160686&amp;dopt=Abstract" target="new">[PMID: 
18160686]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952949"></a>Muss HB et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055–65. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19439741&amp;dopt=Abstract" target="new">[PMID: 19439741]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952950"></a>Nelson
JC et al. Four-year clinical update from the American Society of Breast
Surgeons MammoSite brachytherapy trial. Am J Surg. 2009
Jul;198(1):83–91. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19268900&amp;dopt=Abstract" target="new">[PMID: 19268900]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178720"></a>Nielsen KV et al. The value of <i>TOP2A</i> gene 
copy number variation as a biomarker in breast cancer: Update of 
DBCG trial 89D. Acta Oncol. 2008;47(4):725–34. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18465341&amp;dopt=Abstract" target="new">[PMID: 
18465341]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952951"></a>Olson
JA Jr et al. Improved surgical outcomes for breast cancer patients
receiving neoadjuvant aromatase inhibitor therapy: results from a
multicenter phase II trial. J Am Coll Surg. 2009 May;208(5):906–14.
&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19476859&amp;dopt=Abstract" target="new">[PMID: 19476859]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178721"></a>Orlando L et al. Management of advanced breast cancer. Ann Oncol. 
2007 Jun;18(Suppl 6):vi74–6. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17591838&amp;dopt=Abstract" target="new">[PMID: 17591838]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952952"></a>Pal
SK et al. Adjuvant systemic therapy for older adults with early-stage
breast cancer. Womens Health (Lond Engl). 2009 May;5(3):251–62. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19392611&amp;dopt=Abstract" target="new">[PMID: 19392611]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178722"></a>Perez EA et al. Cardiac safety analysis of doxorubicin and cyclophosphamide 
followed by paclitaxel with or without trastuzumab in the North 
Central Cancer Treatment Group N9831 adjuvant breast cancer trial. 
J Clin Oncol. 2008 Mar 10;26(8):1231–8. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18250349&amp;dopt=Abstract" target="new">[PMID: 
18250349]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178725"></a>Pruthi S et al. A multidisciplinary approach to the management 
of breast cancer, part 2: therapeutic considerations. Mayo Clin 
Proc. 2007 Sep;82(9):1131–40. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17803883&amp;dopt=Abstract" target="new">[PMID: 17803883]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178727"></a>Seidman AD. Systemic treatment of breast cancer. Two decades 
of progress. Oncology (Williston Park). 2006 Aug;20(9):983–90. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16986346&amp;dopt=Abstract" target="new">[PMID: 
16986346]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178728"></a>Slamon DJ et al. Advances in adjuvant therapy for breast cancer. 
Clin Adv Hematol Oncol. 2006 Mar;4(3 Suppl 7):suppl 1, 4-9. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16736568&amp;dopt=Abstract" target="new">[PMID: 
16736568]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178729"></a>Slamon 
DJ et al. Use of chemotherapy plus a monoclonal antibody against <i>HER2</i> for metastatic breast cancer that 
overexpresses <i>HER2</i>. N Engl J Med. 2001 
Mar 15;344(11):783–92. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=11248153&amp;dopt=Abstract" target="new">[PMID: 11248153]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178730"></a>Smith I. Goals of treatment for patients with metastatic breast 
cancer. Semin Oncol. 2006 Feb;33(1 Suppl 2):S2–5. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16472711&amp;dopt=Abstract" target="new">[PMID: 16472711]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178731"></a>Smith I et al. 2-year follow-up of trastuzumab after adjuvant 
chemotherapy in HER2-positive breast cancer: a randomised controlled 
trial. Lancet. 2007 Jan 6;369(9555):29–36. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17208639&amp;dopt=Abstract" target="new">[PMID: 
17208639]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178733"></a>Thomas ES et al. Ixabepilone plus capecitabine for metastatic 
breast cancer progressing after anthracycline and taxane treatment. 
J Clin Oncol. 2007 Nov 20;25(33):5210–7. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17968020&amp;dopt=Abstract" target="new">[PMID: 
17968020]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952953"></a>Veronesi
U et al. Breast conservation: current results and future perspectives
at the European Institute of Oncology. Int J Cancer. 2007 Apr
1;120(7):1381–6. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17211883&amp;dopt=Abstract" target="new">[PMID: 17211883]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178734"></a>Veronesi U et al. Lessons from the initial adjuvant cyclophosphamide, 
methotrexate, and fluorouracil studies in operable breast cancer. 
J Clin Oncol. 2008 Jan;26(3):342–4. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=18202404&amp;dopt=Abstract" target="new">[PMID: 18202404]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952954"></a>Von
Minckwitz G et al. Trastuzumab beyond progression in human epidermal
growth factor receptor 2-positive advanced breast cancer: a German
Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol.
2009 Apr 20;27(12):1999–2006. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19289619&amp;dopt=Abstract" target="new">[PMID: 19289619]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178736"></a>Voogd AC et al. Prognosis of patients with locally recurrent 
breast cancer. Am J Surg. 2007 Jan;193(1):138. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17188110&amp;dopt=Abstract" target="new">[PMID: 17188110]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="3178737"></a>Waljee JF et al. Neoadjuvant systemic therapy and the surgical 
management of breast cancer. Surg Clin North Am. 2007 Apr;87(2):399–415. 
					&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17498534&amp;dopt=Abstract" target="new">[PMID: 
17498534]</a><br><br class="Spacer10"></td></tr></tbody></table><a name="8742"></a>
			<p class="contentHead3">Prognosis</p><a name="8743"></a><p class="contentBody">Stage of breast cancer is the most reliable indicator of prognosis 
(<a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8744');">Table 17–6</a>).
Axillary lymph node status is the best-analyzed prognostic factor and
correlates with survival at all tumor sizes. When cancer is localized
to the breast, with no evidence of regional spread after pathologic
examination, the clinical cure rate with most accepted methods of
therapy is 75% to &gt; 90%. In fact, patients with small
mammographically detected biologically favorable tumors and no evidence
of axillary spread have a 5-year survival rate &gt; 95%. When the
axillary lymph nodes are involved with tumor, the survival rate drops
to 50–70% at 5 years and probably around 25–40% at 10 years.
Increasingly, the use of biologic markers, such as ER, PR, grade, and
HER-2/neu, is helping to identify high-risk tumor types as well as
direct treatment used (see <a href="http://www.accessmedicine.com/content.aspx?aID=8680#8680" target="_parent">Biomarkers &amp; Gene Expression Profiling</a>). Tumors with marked aneuploidy have a poor prognosis (see <a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8712');">Table 17–4</a>). Gene analysis studies, 
such as Oncotype Dx, can predict disease-free survival for some 
subsets of patients.</p><table border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><a href="javascript:windowReference('Reference',%20'popup.aspx?aID=8744');" border="0"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_table.gif" border="0"></a></td><td class="font11" align="left" valign="middle"><b><a href="javascript:windowReference('Reference','popup.aspx?aID=8744');"><b><font class="font12">Table 17–6.&nbsp;Approximate 
survival (%) of patients with breast cancer by TNM stage.</font></b></a></b></td></tr></tbody></table><a name="8745"></a><p class="contentBody">The
mortality rate of breast cancer patients exceeds that of age-matched
normal controls for nearly 20 years. Thereafter, the mortality rates
are equal, though deaths that occur among breast cancer patients are
often directly the result of tumor. Five-year statistics do not
accurately reflect the final outcome of therapy.</p><a name="8746"></a><p class="contentBody">In general, breast cancer 
appears to be somewhat more malignant in younger than in older women, 
and this may be related to the fact that fewer younger women have 
ER-positive tumors. Adjuvant systemic chemotherapy, in general, 
improves survival by about 30% and adjuvant hormonal therapy 
by about 25%.</p><a name="8747"></a><p class="contentBody">For those patients whose disease progresses despite treatment, 
studies suggest supportive group therapy may improve survival. As 
they approach the end of life, such patients will require meticulous 
palliative care (see <a href="http://www.accessmedicine.com/content.aspx?aID=586#586" target="_parent">Chapter 5: Palliative Care &amp; Pain Management</a>).</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top">Stuart K et al. Life after breast cancer. Aust 
Fam Physician. 2006 Apr;35(4):219–24.
				&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16642238&amp;dopt=Abstract" target="new">[PMID: 
16642238]</a><br><br class="Spacer10"></td></tr></tbody></table><a name="8748"></a>
			<p class="contentHead3">Follow-Up Care</p><a name="8749"></a><p class="contentBody">After
primary therapy, patients with breast cancer should be monitored
long-term in order to detect recurrences and to observe the opposite
breast for a second primary carcinoma. Local and distant recurrences
occur most frequently within the first 2–5 years. During the first 2
years, most patients should be examined every 6 months (with mammogram
every 6 months on the affected breast), then annually thereafter. The
patient should examine her own breasts monthly, and a mammogram should
be obtained annually. Special attention is paid to the contralateral
breast because a new primary breast malignancy will develop in 20–25%
of patients. In some cases, metastases are dormant for long periods and
may appear 10–15 years or longer after removal of the primary tumor.
Although studies have failed to show an adverse effect of hormonal
replacement in disease-free patients, it is rarely used after breast
cancer treatment, particularly if the tumor was hormone receptor
positive. Even pregnancy has not been associated with shortened
survival of patients rendered disease free—yet many oncologists are
reluctant to advise a young patient with breast cancer that it is safe
to become pregnant, and most will not support prescribing hormone
replacement for the postmenopausal breast cancer patient. The use of
estrogen replacement for conditions such as osteoporosis and hot
flushes may be considered for a woman with a history of breast cancer
after discussion of the benefits and risks, but it is not routinely
recommended. </p><a name="8750"></a>
				<p class="contentHead5">Local Recurrence</p><a name="8751"></a><p class="contentBody">The incidence of local recurrence correlates with tumor size, 
the presence and number of involved axillary nodes, the histologic 
type of tumor, the presence of skin edema or skin and fascia fixation 
with the primary tumor, and the type of definitive surgery and local 
irradiation. Local recurrence on the chest wall after total mastectomy 
and axillary dissection develops in as many as 8% of patients. 
When the axillary nodes are not involved, the local recurrence rate 
is &lt; 5%, but the rate is as high as 25% when 
they are heavily involved. A similar difference in local recurrence 
rate was noted between small and large tumors. Factors such as multifocal 
cancer, in situ tumors, positive resection margins, chemotherapy, 
and radiotherapy have an effect on local recurrence in patients 
treated with breast-conserving surgery.</p><a name="8752"></a><p class="contentBody">Chest wall recurrences usually appear within the first several 
years but may occur as late as 15 or more years after mastectomy. 
All suspicious nodules and skin lesions should be biopsied. Local 
excision or localized radiotherapy may be feasible if an isolated 
nodule is present. If lesions are multiple or accompanied by evidence 
of regional involvement in the internal mammary or supraclavicular 
nodes, the disease is best managed by radiation treatment of the 
entire chest wall including the parasternal, supraclavicular, and 
axillary areas and usually by systemic therapy.</p><a name="8753"></a><p class="contentBody">Local recurrence after mastectomy usually signals the presence 
of widespread disease and is an indication for studies to search 
for evidence of metastases. Distant metastases will develop within 
a few years in most patients with locally recurrent tumor after 
mastectomy. When there is no evidence of metastases beyond the chest 
wall and regional nodes, irradiation for cure after complete local 
excision should be attempted. After partial mastectomy, 
local recurrence does not have as serious a prognostic significance 
as after mastectomy. However, those patients in whom a recurrence 
develops have a worse prognosis than those who do not. It is speculated 
that the ability of a cancer to recur locally after radiotherapy 
is a sign of aggressiveness and resistance to therapy. Completion 
of the mastectomy should be done for local recurrence after partial 
mastectomy; some of these patients will survive for prolonged periods, 
especially if the breast recurrence is DCIS or occurs more than 5 
years after initial treatment. Systemic chemotherapy or hormonal 
treatment should be used for women in whom disseminated disease 
develops or those in whom local recurrence occurs.</p><a name="8754"></a>
				<p class="contentHead5">Breast Cancer Survivorship Issues</p><a name="8952981"></a><p class="contentBody">Given
that most women with non-metastatic breast cancer will be cured, a
significant number of women face survivorship issues stemming from
either the diagnosis or the treatment of the breast cancer. These
challenges include psychological struggles, upper extremity lymphedema,
cognitive decline (also called “chemo brain”), weight management
problems, cardiovascular issues, bone loss, postmenopausal side
effects, and fatigue. One randomized study reported that survivors who
received psychological intervention from the time of diagnosis had a
lower risk of recurrence and breast cancer-related mortality. A
randomized study in older, overweight cancer survivors showed that diet
and exercise reduced the rate of self-reported functional decline
compared with no intervention. Cognitive dysfunction is a commonly
reported symptom experienced by women who have undergone systemic
treatment for early breast cancer. Studies are ongoing to understand
the pathophysiology leading to this syndrome. An interesting study
reported that 200 mg of modafinil daily improved speed and quality of
memory as well as attention for breast cancer survivors dealing with
cognitive dysfunction. This promising study requires validation in a
larger clinical trial.</p><a name="8952982"></a><p class="contentHead8">Edema of the arm</p><a name="8755"></a><p class="contentBody">Significant edema of the arm occurs in about 10–30% of 
patients after axillary dissection with or without mastectomy. It 
occurs more commonly if radiotherapy has been given or if there 
was postoperative infection. Partial mastectomy with radiation to 
the axillary lymph nodes is followed by chronic edema of the arm 
in 10–20% of patients. Sentinel lymph node dissection 
has proved to be a more accurate form of axillary staging without 
the side effects of edema or infection. It does not replace axillary 
dissection if the sentinel lymph nodes are involved with metastases. 
Judicious use of radiotherapy, with treatment fields carefully planned 
to spare the axilla as much as possible, can greatly diminish the 
incidence of edema, which will occur in only 5% of patients 
if no radiotherapy is given to the axilla after a partial mastectomy 
and lymph node dissection.</p><a name="8756"></a><p class="contentBody">Late
or secondary edema of the arm may develop years after treatment, as a
result of axillary recurrence or infection in the hand or arm, with
obliteration of lymphatic channels. When edema develops, a careful
examination of the axilla for recurrence or infection is performed.
Infection in the arm or hand on the dissected side should be treated
with antibiotics, rest, and elevation. If there is no sign of
recurrence or infection, the swollen extremity should be treated with
rest and elevation. A mild diuretic may be helpful. If there is no
improvement, a compressor pump or manual compression decreases the
swelling, and the patient is then fitted with an elastic glove or
sleeve. Most patients are not bothered enough by mild edema to wear an
uncomfortable glove or sleeve and will treat themselves with elevation
or manual compression alone. Benzopyrones have been reported to
decrease lymphedema but are not approved for this use in the United
States. Rarely, edema may be severe enough to interfere with use of the
limb. Traditionally, patients were advised to avoid weight lifting with
the ipsilateral arm to prevent a worsening in lymphedema. However, a
prospective randomized study has shown that twice weekly progressive
weight lifting improves lymphedema symptoms and exacerbations and
improves extremity strength. </p><a name="8757"></a>
					<p class="contentHead8">Breast reconstruction</p><a name="8758"></a><p class="contentBody">Breast reconstruction is usually feasible after total or modified 
radical mastectomy. Reconstruction should be discussed with patients 
prior to mastectomy, because it offers an important psychological focal 
point for recovery. Reconstruction is not an obstacle to the diagnosis 
of recurrent cancer. The most common breast reconstruction has been 
implantation of a silicone gel or saline prosthesis in the subpectoral 
plane between the pectoralis minor and pectoralis major muscles. 
Alternatively, autologous tissue can be used for reconstruction.</p><a name="3175511"></a><p class="contentBody">Autologous tissue flaps are aesthetically superior to implant 
reconstruction in most patients. They also have the advantage of 
not feeling like a foreign body to the patient. The most popular 
autologous technique currently is the trans-rectus abdominis muscle flap 
(TRAM flap), which is done by rotating the rectus abdominis muscle 
with attached fat and skin cephalad to make a breast mound. The 
free TRAM flap is done by completely removing a small portion of 
the rectus with overlying fat and skin and using microvascular surgical 
techniques to reconstruct the vascular supply on the chest wall. 
A latissimus dorsi flap can be swung from the back but offers less 
fullness than the TRAM flap and is therefore less acceptable cosmetically. 
An implant often is used to increase the fullness with a latissimus 
dorsi flap. Reconstruction may be performed immediately (at the time 
of initial mastectomy) or may be delayed until later, usually when 
the patient has completed adjuvant therapy. When considering reconstructive 
options, concomitant illnesses should be considered, since the ability 
of an autologous flap to survive depends on medical comorbidities. 
In addition, the need for radiotherapy may affect the choice of 
reconstruction as radiation may increase fibrosis around an implant 
or decrease the volume of a flap.</p><a name="8760"></a>
					<p class="contentHead8">Risks of pregnancy</p><a name="8761"></a><p class="contentBody">Data
are insufficient to determine whether interruption of pregnancy
improves the prognosis of patients who are identified to have
potentially curable breast cancer and who receive definitive treatment
during pregnancy. Theoretically, the high levels of estrogen produced
by the placenta as the pregnancy progresses could be detrimental to the
patient with occult metastases of hormone-sensitive breast cancer.
However, retrospective studies have <i>not</i> shown a worse prognosis
for women with gestational breast cancer. The decision whether or not
to terminate the pregnancy must be made on an individual basis, taking
into account the clinical stage of the cancer, the overall prognosis
for the patient, the gestational age of the fetus, the potential for
premature ovarian failure in the future with systemic therapy, and the
patient’s wishes. Women with early-stage gestational breast cancer who
choose to continue their pregnancy should undergo surgery to remove the
tumor and systemic therapy if indicated. Retrospective reviews of
patients treated with anthracycline-containing regimens for gestational
cancers (including leukemia and lymphomas) have established the
relative safety of these regimens during pregnancy for both the patient
and the fetus. Taxane-based regimens have not been evaluated
extensively, however. Obviously, radiation therapy should be delayed
until the pregnant patient has delivered. </p><a name="8762"></a><p class="contentBody">Equally
important is the advice regarding future pregnancy (or abortion in case
of pregnancy) to be given to women of child-bearing age who have had
definitive treatment for breast cancer. To date, no adverse effect of
pregnancy on survival of women who have had breast cancer has been
demonstrated. When counseling patients, oncologists must take into
consideration the patients’ overall prognosis, age, comorbidities, and
life goals. </p><a name="8763"></a><p class="contentBody">In patients
with inoperable or metastatic cancer (stage IV disease), induced
abortion is usually advisable because of the possible adverse effects
of hormonal treatment, radiotherapy, or chemotherapy upon the fetus in
addition to the expectant mother’s poor prognosis.</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="contentBody" valign="top"><a name="8952955"></a>Andersen
BL et al. Psychologic intervention improves survival for breast cancer
patients: a randomized clinical trial. Cancer. 2008 Dec
15;113(12):3450–8. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19016270&amp;dopt=Abstract" target="new">[PMID: 19016270]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Banks E et al. Pregnancy in women with a history 
of breast cancer. BMJ. 2007 Jan 27;334(7586):166–7.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17255571&amp;dopt=Abstract" target="new">[PMID: 17255571]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Dian D et al. Quality of life among breast cancer patients undergoing 
autologous breast reconstruction versus breast conserving therapy. 
J Cancer Res Clin Oncol. 2007 Apr;133 (4):247–52.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17096124&amp;dopt=Abstract" target="new">[PMID: 
17096124]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Hu E et al. Breast reconstruction. Surg Clin North Am. 2007 Apr;87(2):453–67.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17498537&amp;dopt=Abstract" target="new">[PMID: 
17498537]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952956"></a>Kohli S et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009 Jun 15;115(12):2605–16. 
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19309747&amp;dopt=Abstract" target="new">[PMID: 19309747]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Kronowitz SJ et al. Advances and surgical decision-making for breast 
reconstruction. Cancer. 2006 Sep 1;107(5):893–907.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16862569&amp;dopt=Abstract" target="new">[PMID: 
16862569]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952957"></a>Morey
MC et al. Effects of home-based diet and exercise on functional
outcomes among older, overweight long-term cancer survivors: RENEW: a
randomized controlled trial. JAMA. 2009 May 13;301(18):1883–91. &nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19436015&amp;dopt=Abstract" target="new">[PMID: 19436015]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Moseley AL et al. A systematic review of common conservative 
therapies for arm lymphoedema secondary to breast cancer treatment. 
Ann Oncol. 2007 Apr;18(4):639–46.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17018707&amp;dopt=Abstract" target="new">[PMID: 
17018707]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Pomahac B et al. New trends in breast cancer management: is the 
era of immediate breast reconstruction changing? Ann Surg. 2006 
Aug;244(2):282–8.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16858192&amp;dopt=Abstract" target="new">[PMID: 16858192]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Sakorafas GH et al. Lymphedema following axillary lymph node 
dissection for breast cancer. Surg Oncol. 2006 Nov;15(3):153–65.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17187979&amp;dopt=Abstract" target="new">[PMID: 
17187979]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Salhab M et al. Skin-sparing mastectomy and immediate breast reconstruction: 
patient satisfaction and clinical outcome. Int J Clin Oncol. 2006 
Feb;11(1):51–4.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=16508729&amp;dopt=Abstract" target="new">[PMID: 16508729]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top"><a name="8952958"></a>Schmitz KH et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009 Aug 13;361(7):664–73. 
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=19675330&amp;dopt=Abstract" target="new">[PMID: 19675330]</a><br><br class="Spacer10"></td></tr><tr><td class="contentBody" valign="top">Soran A et al. Breast cancer-related lymphedema—what 
are the significant predictors and how they affect the severity 
of lymphedema? Breast J. 2006 Nov–Dec;12(6):536–43.
						&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Retrieve&amp;list_uids=17238983&amp;dopt=Abstract" target="new">[PMID: 
17238983]</a><br><br class="Spacer10"></td></tr></tbody></table></td></tr></tbody></table></span>
																		</td>
																	</tr>
																</tbody></table>
																<br class="Spacer10">
																<table id="ctl00_divMainContentWrapper_tblSectionNavigationBottom" border="0" cellpadding="0" cellspacing="0" width="100%">
			<tbody><tr>
				<td><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td>
				<td class="navlinks" align="center" width="100%"><a id="ctl00_divMainContentWrapper_lnkPreviousTop2" href="http://www.accessmedicine.com/content.aspx?aID=8588"><font class="font12noMargin">&lt;</font>&nbsp;<b>Previous 
																					Section</b></a>&nbsp;<font color="#999999">|</font>&nbsp;<a id="ctl00_divMainContentWrapper_lnkNextTop2" href="http://www.accessmedicine.com/content.aspx?aID=8764"><b>Next 
																					Section</b>&nbsp;<font class="font12noMargin">&gt;</font></a></td>
			</tr>
		</tbody></table>
		
																<br class="Spacer10">
																<table border="0" cellpadding="0" cellspacing="0" width="100%">
																	<tbody><tr>
																		<td style="height: 18px;"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="10"></td>
																		<td style="height: 18px;" align="right" width="100%">
																			<a href="javascript:windowNonResizable('citeThis',500,250,'citepopup.aspx?aid=8538&amp;citeType=1',%20true);" id="ctl00_divMainContentWrapper_hrefCiteBottom"><img src="Chapter%2017.%20Breast%20Disorders_archivos/newb_howtocite.gif" id="ctl00_divMainContentWrapper_imgCiteBottom" border="0"></a>&nbsp;<a href="javascript:windowReference('Print','popup.aspx?aID=8592&amp;print=yes');" id="ctl00_divMainContentWrapper_hrefPrintSectionBottom"><img name="print" src="Chapter%2017.%20Breast%20Disorders_archivos/newb_printsection.gif" onmouseover="print.src='images/newb_printsection_over.gif';" onmouseout="print.src='images/newb_printsection.gif';" border="0"></a>&nbsp;<a href="javascript:windowReference('Print','popup.aspx?aID=8592&amp;print=yes_chapter');" id="ctl00_divMainContentWrapper_hrefPrintChapterBottom"><img name="print" src="Chapter%2017.%20Breast%20Disorders_archivos/newb_printchapter.gif" onmouseover="print.src='images/newb_printchapter_over.gif';" onmouseout="print.src='images/newb_printchapter.gif';" border="0"></a>&nbsp;<a href="javascript:windowReference('Print','emailtocolleague.aspx?topicTitle=Carcinoma+of+the+Female+Breast&amp;aID=8612',true);" onmouseover="email.src='images/newb_email_over.gif';" onmouseout="email.src='images/newb_email.gif';"><img name="email" src="Chapter%2017.%20Breast%20Disorders_archivos/newb_email.gif" border="0"></a>&nbsp;<a href="javascript:windowNonResizable('MyAccessMedicineLogin',%20500,%20250,%20'loginPopup.aspx',%20true);"><img src="Chapter%2017.%20Breast%20Disorders_archivos/newb_bookmark.gif" id="ctl00_divMainContentWrapper_imgBookmark2" name="bookmark" border="0"></a>&nbsp;<a href="javascript:windowReference('','/pdaDownload.aspx?aid=8592')"><img src="Chapter%2017.%20Breast%20Disorders_archivos/newb_pda.gif" id="ctl00_divMainContentWrapper_pda2" name="pda2" onmouseover="pda.src='images/newb_pda_over.gif';" onmouseout="pda.src='images/newb_pda.gif';" border="0"></a>
																		</td>
																	</tr>
																</tbody></table>
																<br class="Spacer10">
															</td>
														</tr>
														<tr>
															
														</tr>
													</tbody></table>
													<table style="border-top: 1px solid rgb(153, 153, 153); border-bottom: 1px solid rgb(153, 153, 153);" border="0" cellpadding="0" cellspacing="0" width="100%">
														<tbody><tr>
															<td>
																<table style="border-top: 1px solid rgb(255, 255, 255); border-bottom: 1px solid rgb(255, 255, 255);" bgcolor="#d1d8de" border="0" cellpadding="5" cellspacing="0" width="100%">
																	<tbody><tr>
																		<td>
																			<table border="0" cellpadding="0" cellspacing="0" width="100%">
																				<tbody><tr>
																					<td><span id="ctl00_divMainContentWrapper_lblBookCoverImage2"><img src="Chapter%2017.%20Breast%20Disorders_archivos/covermed_cmdt.gif" border="0"></span></td>
																					<td><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" width="5"></td>
																					<td class="font11noMargin" width="100%"><span id="ctl00_divMainContentWrapper_lblChapterLinks2"><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="breadcrumbs"><a href="http://www.accessmedicine.com/resourceTOC.aspx?resourceID=1" class="solid"><b>CURRENT Medical Dx &amp; Tx</b></a>&nbsp;&gt;</td><td width="10"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" border="0" width="10"></td></tr></tbody></table></span></td>
																				</tr>
																			</tbody></table>
																		</td>
																	</tr>
																</tbody></table>
															</td>
														</tr>
													</tbody></table>
												</td>
	</tr>
</tbody></table>

										
									</td>
								</tr>
							</tbody></table>
						</td>
					</tr>
		</tbody></table>


            </div>
            </div>
        <div id="leftcolumnmaster">
            <img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" alt="" style="width: 20px;">
        </div>
        <div id="rightcolumnmaster">
            <img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" alt="" style="width: 30px;">
        </div>
        <div id="footermaster">
<div style="margin-left: 30px; margin-right: 30px;" class="font11">
    <div style="border-top: 1px solid rgb(204, 204, 204); height: 1px;"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" style="width: 1px; height: 1px;" alt=""></div>
    <div style="clear: both;"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" alt="" style="height: 10px;"></div>
    <div style="float: left;">
        Copyright © The McGraw-Hill Companies. All rights reserved.<br>
        <a href="http://www.accessmedicine.com/public/privacy.aspx">Privacy Notice</a>. Any use is subject to the <a href="http://www.accessmedicine.com/public/termsofuse.aspx">Terms of Use</a> and <a href="http://www.accessmedicine.com/public/notice.aspx">Notice</a>.<br>
        <a href="http://www.silverchair.com/" target="_blank"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_silverchair.gif" alt="" style="border: 0pt none ; margin-top: 10px;"></a>
    </div>
    <div style="float: right;">
        <a href="http://www.mcgrawhill.com/" target="_blank"><img src="Chapter%2017.%20Breast%20Disorders_archivos/icon_MGHcompanies.jpg" alt="" style="border: 0pt none ;"></a>
    </div>
    <div style="clear: both;"><img src="Chapter%2017.%20Breast%20Disorders_archivos/spacer.gif" alt="" style="height: 10px;"></div>
</div>
<!-- Google Analytics -->
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script><script src="Chapter%2017.%20Breast%20Disorders_archivos/ga.js" type="text/javascript"></script>
<script type="text/javascript">
try {
var pageTracker = _gat._getTracker("UA-7175171-4");
pageTracker._trackPageview();
} catch(err) {}
</script>

</div>
        </div>
    

<script type="text/javascript">
//<![CDATA[
Sys.Application.initialize();
Sys.Application.add_init(function() {
    $create(Telerik.Web.UI.RadWindowManager, {"behaviors":4,"clientStateFieldID":"ctl00_ucheader1_RadWindowManager1_ClientState","formID":"aspnetForm","iconUrl":"","left":"","minimizeIconUrl":"","name":"RadWindowManager1","skin":"Web20","top":"","windowControls":"[]"}, null, null, $get("ctl00_ucheader1_RadWindowManager1"));
});

WebForm_InitCallback();Sys.Application.add_init(function() {
    $create(Telerik.Web.UI.RadComboBox, {"_dropDownWidth":0,"_height":0,"_skin":"Default","_text":"mammography","_uniqueId":"ctl00$ucheader1$RadComboBox2","_value":"","_virtualScroll":false,"allowCustomText":true,"clientStateFieldID":"ctl00_ucheader1_RadComboBox2_ClientState","collapseAnimation":"{\"duration\":450}","expandAnimation":"{\"duration\":450}","itemData":[],"webServiceSettings":"{\"path\":\"/webservices/SearchServices.asmx\",\"method\":\"GetSearchSuggestions\"}"}, {"dropDownOpening":OnClientDropDownOpening,"itemsRequesting":PrepareForAutoComp,"keyPressing":headerCheckSearchEnter,"selectedIndexChanged":OnClientSelectedIndexChanged}, null, $get("ctl00_ucheader1_RadComboBox2"));
});
Sys.Application.add_init(function() {
    $create(Telerik.Web.UI.RadComboBox, {"_dropDownWidth":0,"_height":0,"_skin":"Vista","_text":"All AccessMedicine","_uniqueId":"ctl00$ucheader1$RadcboSource","_value":"0","_virtualScroll":false,"clientStateFieldID":"ctl00_ucheader1_RadcboSource_ClientState","collapseAnimation":"{\"duration\":450}","expandAnimation":"{\"duration\":450}","itemData":[{"value":"0","selected":true},{"value":"1"},{"value":"2"},{"value":"3"},{"value":"4"},{"value":"5"},{"value":"6"},{"value":"7"},{"value":"8"},{"value":"9"},{"value":"10"}],"selectedIndex":0}, null, null, $get("ctl00_ucheader1_RadcboSource"));
});
//]]>
</script>
</form>
</body></html>